Index S&P 500
P/E 20.63
EPS (ttm) 7.41
Insider Own 0.49%
Shs Outstand 111.00M
Perf Week -2.11%
Market Cap 17.02B
Forward P/E 15.89
EPS next Y 9.62
Insider Trans -6.31%
Shs Float 110.77M
Perf Month 4.65%
Income 836.00M
PEG 3.15
EPS next Q 2.28
Inst Own 92.53%
Short Float 2.52%
Perf Quarter 7.21%
Sales 9.35B
P/S 1.82
EPS this Y 2.48%
Inst Trans -1.34%
Short Ratio 3.35
Perf Half Y 20.05%
Book/sh 59.61
P/B 2.57
EPS next Y 7.79%
ROA 6.12%
Short Interest 2.79M
Perf Year 20.28%
Cash/sh 2.43
P/C 62.82
EPS next 5Y 6.55%
ROE 13.00%
52W Range 119.59 - 159.36
Perf YTD 10.92%
Dividend Est. 2.91 (1.90%)
P/FCF 19.46
EPS past 5Y 7.36%
ROI 7.64%
52W High -4.03%
Beta 0.89
Dividend TTM 2.92 (1.91%)
Quick Ratio 0.91
Sales past 5Y 4.86%
Gross Margin 31.81%
52W Low 27.88%
ATR (14) 2.64
Dividend Ex-Date Oct 04, 2024
Current Ratio 1.00
EPS Y/Y TTM 7.62%
Oper. Margin 14.49%
RSI (14) 54.51
Volatility 1.92% 1.56%
Employees 48000
Debt/Eq 0.77
Sales Y/Y TTM -1.50%
Profit Margin 8.95%
Recom 2.35
Target Price 156.00
Option/Short Yes / Yes
LT Debt/Eq 0.65
EPS Q/Q -0.82%
Payout 37.76%
Rel Volume 0.99
Prev Close 154.23
Sales Surprise 0.29%
EPS Surprise 0.65%
Sales Q/Q 2.52%
Earnings Jul 23 BMO
Avg Volume 833.59K
Price 152.93
SMA20 0.12%
SMA50 4.05%
SMA200 11.50%
Trades
Volume 827,453
Change -0.84%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-28-24 Resumed
Evercore ISI
In-line
$165
Jul-10-24 Upgrade
Citigroup
Neutral → Buy
$145 → $165
Feb-26-24 Initiated
Leerink Partners
Market Perform
$135
Feb-07-24 Upgrade
Jefferies
Hold → Buy
$140 → $155
Jan-03-24 Initiated
Barclays
Equal Weight
$145
Dec-12-23 Upgrade
BofA Securities
Neutral → Buy
$140 → $160
Jun-29-23 Initiated
Piper Sandler
Neutral
May-02-23 Downgrade
BofA Securities
Buy → Neutral
$166 → $148
Apr-03-23 Upgrade
Citigroup
Sell → Neutral
$125 → $142
Jan-23-23 Initiated
Evercore ISI
In-line
$159
Nov-17-22 Downgrade
Citigroup
Neutral → Sell
$145 → $125
Aug-22-22 Resumed
Morgan Stanley
Equal-Weight
$142
Apr-04-22 Downgrade
Citigroup
Buy → Neutral
$175 → $140
Feb-23-22 Downgrade
UBS
Buy → Neutral
$160 → $139
Feb-02-22 Downgrade
Jefferies
Buy → Hold
$135
Jan-28-22 Downgrade
Deutsche Bank
Buy → Hold
$190 → $129
May-04-21 Upgrade
UBS
Neutral → Buy
$135 → $158
Mar-12-21 Downgrade
Robert W. Baird
Outperform → Neutral
$137
Oct-21-20 Upgrade
Argus
Hold → Buy
Jul-29-20 Upgrade
KeyBanc Capital Markets
Sector Weight → Overweight
$144
Show Previous Ratings
Sep-05-24 09:40AM
Aug-30-24 09:40AM
Aug-28-24 03:31PM
Aug-27-24 08:23AM
Aug-26-24 08:50AM
08:31AM
Loading…
08:31AM
Aug-23-24 07:53AM
Aug-22-24 11:30AM
10:35AM
09:15AM
Aug-21-24 08:55AM
Aug-19-24 08:07AM
Aug-16-24 06:33AM
Aug-15-24 06:13PM
09:05AM
07:32AM
Loading…
07:32AM
Aug-14-24 07:04PM
09:40AM
Aug-13-24 11:24AM
08:55AM
Aug-12-24 08:51AM
Aug-11-24 07:37AM
Aug-05-24 09:15AM
Aug-01-24 06:48AM
Jul-29-24 09:40AM
08:03AM
Jul-26-24 01:04AM
Jul-25-24 06:45AM
Jul-24-24 07:47AM
03:24AM
12:21AM
Loading…
12:21AM
(Thomson Reuters StreetEvents)
Jul-23-24 10:05AM
07:55AM
06:51AM
(Associated Press Finance)
06:45AM
Jul-18-24 09:00AM
08:00AM
07:30AM
Jul-17-24 09:50AM
06:00AM
Jul-16-24 09:15AM
Jul-15-24 08:35AM
06:17AM
Jul-14-24 12:58PM
12:57PM
Jul-12-24 09:37AM
Jul-11-24 10:55AM
Jul-10-24 08:58AM
Jul-08-24 06:06AM
Jul-04-24 11:15AM
04:12AM
Jul-03-24 08:45AM
Jun-27-24 09:43AM
06:45AM
Jun-26-24 04:03PM
08:35AM
Jun-21-24 11:06AM
Jun-19-24 03:00PM
Jun-18-24 08:58AM
Jun-12-24 11:15AM
Jun-11-24 07:57AM
Jun-10-24 12:30PM
Jun-06-24 10:15AM
Jun-05-24 12:10PM
May-31-24 04:08PM
May-29-24 12:20PM
May-23-24 11:30AM
May-21-24 03:15PM
01:15PM
May-16-24 04:15PM
08:41AM
05:44AM
05:41AM
May-15-24 05:54PM
(The Wall Street Journal)
05:45PM
10:46AM
10:37AM
08:43AM
May-14-24 09:00PM
(The Wall Street Journal)
May-13-24 01:00PM
07:09AM
May-08-24 12:30PM
May-07-24 04:50PM
11:23AM
May-06-24 02:00PM
09:40AM
May-02-24 10:42AM
09:02AM
08:10AM
01:23AM
May-01-24 10:44AM
06:57AM
Apr-30-24 08:37AM
Apr-26-24 08:45AM
01:05AM
Apr-25-24 11:13AM
Apr-24-24 03:02AM
Apr-23-24 10:35PM
(Thomson Reuters StreetEvents) +5.08%
09:58PM
10:52AM
Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
PREVOZNIK MICHAEL E SVP & General Counsel Aug 29 '24 Option Exercise 95.80 32,551 3,118,223 71,029 Sep 03 04:30 PM PREVOZNIK MICHAEL E SVP & General Counsel Aug 29 '24 Sale 154.97 32,551 5,044,516 38,478 Sep 03 04:30 PM KUPPUSAMY KARTHIK SVP, Clinical Solutions Aug 28 '24 Sale 153.26 1,990 304,990 11,459 Aug 29 04:45 PM PREVOZNIK MICHAEL E Officer Aug 29 '24 Proposed Sale 154.97 32,551 5,044,516 Aug 29 01:55 PM KUPPUSAMY KARTHIK Officer Aug 28 '24 Proposed Sale 153.26 1,990 304,990 Aug 28 04:49 PM DELANEY MARK E SVP & Chief Commercial Officer Jul 24 '24 Sale 143.08 420 60,094 5,019 Jul 26 06:33 PM KUPPUSAMY KARTHIK SVP, Clinical Solutions Apr 29 '24 Sale 140.00 1,760 246,400 13,435 May 01 04:26 PM Doherty Catherine T. EVP, Regional Businesses Feb 28 '24 Sale 126.57 5,557 703,349 69,599 Mar 01 04:51 PM Doherty Catherine T. EVP, Regional Businesses Feb 29 '24 Sale 125.88 1,187 149,420 68,412 Mar 01 04:51 PM PREVOZNIK MICHAEL E SVP & General Counsel Feb 29 '24 Sale 125.88 5,611 706,313 38,478 Mar 01 04:50 PM PREVOZNIK MICHAEL E SVP & General Counsel Feb 22 '24 Sale 126.14 661 83,379 40,206 Feb 23 04:35 PM Gregg Vicky B Director Feb 23 '24 Sale 126.64 2,500 316,596 16,329 Feb 23 04:34 PM Doherty Catherine T. EVP, Regional Businesses Feb 22 '24 Sale 126.14 821 103,561 70,800 Feb 23 04:32 PM
Index -
P/E -
EPS (ttm) -2.47
Insider Own 6.08%
Shs Outstand 119.58M
Perf Week -2.88%
Market Cap 13.96B
Forward P/E -
EPS next Y -1.16
Insider Trans -7.92%
Shs Float 116.16M
Perf Month 12.50%
Income -292.12M
PEG -
EPS next Q -0.57
Inst Own 95.48%
Short Float 6.56%
Perf Quarter 3.37%
Sales 1.36B
P/S 10.26
EPS this Y 47.95%
Inst Trans 1.73%
Short Ratio 5.48
Perf Half Y 23.17%
Book/sh 6.78
P/B 16.65
EPS next Y 41.08%
ROA -21.13%
Short Interest 7.62M
Perf Year 94.66%
Cash/sh 7.17
P/C 15.74
EPS next 5Y -
ROE -40.78%
52W Range 36.90 - 124.83
Perf YTD 80.24%
Dividend Est. -
P/FCF -
EPS past 5Y -11.28%
ROI -24.73%
52W High -9.56%
Beta 1.52
Dividend TTM -
Quick Ratio 4.01
Sales past 5Y 33.95%
Gross Margin 53.85%
52W Low 205.96%
ATR (14) 5.01
Dividend Ex-Date -
Current Ratio 4.14
EPS Y/Y TTM 48.84%
Oper. Margin -23.06%
RSI (14) 47.13
Volatility 4.95% 4.49%
Employees 3293
Debt/Eq 0.52
Sales Y/Y TTM 46.13%
Profit Margin -21.47%
Recom 1.45
Target Price 130.26
Option/Short Yes / Yes
LT Debt/Eq 0.41
EPS Q/Q 68.71%
Payout -
Rel Volume 0.68
Prev Close 117.50
Sales Surprise 20.51%
EPS Surprise 56.44%
Sales Q/Q 58.13%
Earnings Aug 08 AMC
Avg Volume 1.39M
Price 112.90
SMA20 -4.61%
SMA50 1.42%
SMA200 26.11%
Trades
Volume 946,321
Change -3.91%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-03-24 Resumed
Jefferies
Buy
$142
Apr-08-24 Resumed
Craig Hallum
Buy
$117
Feb-20-24 Downgrade
Raymond James
Strong Buy → Outperform
$68 → $85
Dec-29-23 Reiterated
BTIG Research
Buy
$75 → $85
Dec-14-23 Initiated
Guggenheim
Buy
$70
Dec-13-23 Initiated
Wolfe Research
Outperform
$70
Nov-13-23 Upgrade
Raymond James
Outperform → Strong Buy
$68
Sep-28-23 Initiated
Bernstein
Mkt Perform
$48
Jul-05-23 Resumed
JP Morgan
Overweight
$85
May-05-23 Initiated
UBS
Buy
$76
Jan-18-23 Upgrade
Raymond James
Mkt Perform → Outperform
$58
Aug-25-22 Initiated
Credit Suisse
Outperform
$70
Apr-25-22 Initiated
Stephens
Overweight
$54
Mar-08-22 Initiated
Goldman
Buy
$90
Jan-06-22 Resumed
Piper Sandler
Overweight
$110
Oct-15-21 Resumed
Cowen
Outperform
$150
Jun-15-21 Initiated
Raymond James
Mkt Perform
May-25-21 Initiated
Wells Fargo
Overweight
$110
Jan-28-21 Initiated
Truist
Buy
$143
Oct-08-20 Initiated
BTIG Research
Buy
$90
Show Previous Ratings
Sep-06-24 10:24AM
Sep-03-24 02:37AM
Aug-31-24 11:48AM
Aug-29-24 02:07PM
Aug-28-24 09:00AM
03:19PM
Loading…
Aug-27-24 03:19PM
03:16PM
Aug-17-24 01:01AM
Aug-10-24 01:01AM
Aug-09-24 09:46AM
(Thomson Reuters StreetEvents) +6.38%
Aug-08-24 07:00PM
05:19PM
(Associated Press Finance)
04:05PM
Aug-06-24 09:00AM
Jul-30-24 04:05PM
10:53AM
Loading…
Jul-29-24 10:53AM
Jul-27-24 01:00AM
Jul-26-24 08:00AM
Jul-25-24 10:02AM
Jul-18-24 01:00AM
Jul-08-24 09:00AM
Jul-03-24 08:53AM
07:00AM
05:30AM
Jun-27-24 07:00AM
Jun-19-24 03:10AM
Jun-17-24 07:00AM
Jun-10-24 02:25PM
Jun-03-24 08:00AM
02:42AM
03:24AM
Loading…
Jun-01-24 03:24AM
May-31-24 03:13AM
May-30-24 08:00AM
May-23-24 04:05PM
07:30AM
May-18-24 03:00AM
May-16-24 05:23PM
May-11-24 01:02AM
May-10-24 04:01PM
(Investor's Business Daily) +10.19%
01:58PM
(The Wall Street Journal)
12:24PM
12:17PM
(Associated Press Finance)
12:04PM
09:48AM
07:30AM
06:00AM
May-09-24 06:30PM
04:47PM
(Associated Press Finance)
04:05PM
May-03-24 08:00AM
May-02-24 02:14PM
02:50AM
02:49AM
May-01-24 04:05PM
07:00AM
Apr-27-24 02:42AM
Apr-26-24 06:32PM
Apr-24-24 08:36AM
02:38AM
02:38AM
Apr-22-24 08:00AM
Apr-18-24 02:05AM
Apr-17-24 08:31AM
Apr-11-24 08:00AM
Apr-09-24 07:37AM
Apr-08-24 08:00AM
Apr-05-24 07:00AM
05:15AM
01:51AM
Apr-01-24 08:00AM
Mar-21-24 10:25AM
Mar-20-24 05:46AM
Mar-18-24 03:39PM
(Investor's Business Daily)
07:00AM
Mar-14-24 08:00AM
Mar-12-24 08:00AM
Mar-11-24 02:22PM
Mar-08-24 01:31AM
Mar-07-24 08:00AM
Mar-04-24 12:00PM
Mar-01-24 12:09AM
Feb-29-24 11:06AM
(Thomson Reuters StreetEvents) +12.98%
08:12AM
08:00AM
Feb-28-24 06:30PM
04:32PM
04:05PM
Feb-27-24 08:12AM
08:00AM
01:07AM
Feb-26-24 07:00AM
Feb-20-24 08:00AM
Feb-17-24 12:07AM
Feb-06-24 04:00PM
Feb-05-24 08:00AM
Feb-02-24 11:02PM
Jan-31-24 05:02PM
Jan-30-24 09:15AM
07:00AM
Jan-29-24 07:00AM
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Chapman Steven Leonard CEO AND PRESIDENT Aug 15 '24 Sale 118.91 5,583 663,895 200,710 Aug 16 09:40 PM Sheena Jonathan CO-FOUNDER Aug 15 '24 Sale 121.01 12,000 1,452,125 287,441 Aug 16 09:40 PM STEVEN L CHAPMAN Officer Aug 15 '24 Proposed Sale 118.91 5,583 663,895 Aug 15 04:32 PM Sheena Jonathan CO-FOUNDER Aug 12 '24 Sale 113.82 2,700 307,314 299,441 Aug 14 09:05 PM Fesko John PRESIDENT, CHIEF BUS. OFFICER Aug 13 '24 Sale 116.67 3,956 461,547 114,606 Aug 14 09:05 PM Sheena Jonathan Director Aug 12 '24 Proposed Sale 117.68 22,800 2,683,200 Aug 12 10:40 AM Rabinowitz Matthew EXECUTIVE CHAIRMAN Aug 08 '24 Option Exercise 5.40 190,000 1,025,107 1,480,648 Aug 09 09:40 PM RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER Jul 29 '24 Sale 102.77 1,057 108,623 206,400 Jul 31 09:05 PM Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS Jul 29 '24 Sale 102.77 1,196 122,908 112,441 Jul 31 09:05 PM Fesko John PRESIDENT, CHIEF BUS. OFFICER Jul 31 '24 Option Exercise 5.40 100 540 108,562 Jul 31 09:05 PM Fesko John PRESIDENT, CHIEF BUS. OFFICER Jul 29 '24 Sale 102.77 929 95,469 108,462 Jul 31 09:05 PM Chapman Steven Leonard CEO AND PRESIDENT Jul 29 '24 Sale 102.77 4,084 419,695 206,293 Jul 31 09:05 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Jul 31 '24 Sale 99.65 1,866 185,947 71,955 Jul 31 09:05 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Jul 29 '24 Sale 102.77 1,238 127,224 73,821 Jul 31 09:05 PM MICHAEL BURKES BROPHY Officer Jul 31 '24 Proposed Sale 97.75 1,866 182,402 Jul 31 04:17 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Jul 24 '24 Sale 105.53 918 96,877 76,500 Jul 26 09:40 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Jul 26 '24 Sale 102.18 751 76,737 75,059 Jul 26 09:40 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Jul 25 '24 Sale 105.29 690 72,650 75,810 Jul 26 09:40 PM MICHAEL BURKES BROPHY Officer Jul 26 '24 Proposed Sale 102.15 751 76,715 Jul 26 04:17 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Jul 22 '24 Sale 105.16 1,059 111,364 77,917 Jul 23 09:40 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Jul 23 '24 Sale 107.40 499 53,592 77,418 Jul 23 09:40 PM Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS Jul 22 '24 Sale 105.16 549 57,733 113,637 Jul 23 09:05 PM Fesko John PRESIDENT, CHIEF BUS. OFFICER Jul 22 '24 Sale 105.16 549 57,732 109,391 Jul 23 09:05 PM Chapman Steven Leonard CEO AND PRESIDENT Jul 22 '24 Sale 105.16 2,638 277,410 210,377 Jul 23 09:05 PM RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER Jul 22 '24 Sale 105.16 815 85,704 207,457 Jul 23 09:05 PM Chapman Steven Leonard CEO AND PRESIDENT Jul 15 '24 Sale 111.66 5,496 613,672 207,855 Jul 17 09:05 PM Sheena Jonathan CO-FOUNDER Jul 01 '24 Sale 108.87 2,700 293,945 301,808 Jul 02 09:05 PM RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER Jul 01 '24 Sale 108.37 2,723 295,080 206,772 Jul 02 09:05 PM Chapman Steven Leonard CEO AND PRESIDENT Jul 01 '24 Sale 108.10 37,500 4,053,805 213,351 Jul 02 09:05 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Jul 01 '24 Sale 108.37 4,983 539,987 75,059 Jul 02 09:05 PM Sheena Jonathan CO-FOUNDER Jun 18 '24 Sale 109.66 2,700 296,080 304,508 Jun 21 09:05 PM Chapman Steven Leonard CEO AND PRESIDENT Jun 17 '24 Sale 111.61 6,105 681,372 213,351 Jun 18 09:35 PM Marcus Gail Boxer Director May 30 '24 Sale 110.17 2,000 220,330 18,634 May 31 09:05 PM Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS May 28 '24 Sale 109.96 1,647 181,103 114,186 May 30 09:05 PM Fesko John PRESIDENT, CHIEF BUS. OFFICER May 28 '24 Sale 109.96 1,438 158,122 109,940 May 30 09:05 PM Chapman Rowan E Director May 28 '24 Sale 109.09 4,856 529,728 5,005 May 30 09:05 PM Sheena Jonathan CO-FOUNDER May 23 '24 Sale 108.30 1,000 108,301 68,582 May 24 09:05 PM Chapman Steven Leonard CEO AND PRESIDENT May 15 '24 Sale 107.08 6,779 725,911 219,456 May 17 09:35 PM RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER May 10 '24 Option Exercise 19.68 30,000 590,400 234,495 May 10 09:35 PM RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER May 10 '24 Sale 104.59 30,000 3,137,567 204,495 May 10 09:35 PM Sheena Jonathan CO-FOUNDER May 10 '24 Sale 105.11 2,700 283,794 319,061 May 10 09:35 PM Rabinowitz Matthew EXECUTIVE CHAIRMAN May 08 '24 Option Exercise 5.40 215,000 1,159,990 1,290,648 May 10 09:35 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER May 01 '24 Sale 93.97 1,866 175,344 67,542 May 03 09:35 PM Fesko John PRESIDENT, CHIEF BUS. OFFICER Apr 29 '24 Sale 93.14 929 86,526 110,748 May 01 09:05 PM Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS Apr 29 '24 Sale 93.14 1,196 111,394 115,833 May 01 09:05 PM RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER Apr 29 '24 Sale 93.14 1,057 98,448 204,495 May 01 09:05 PM Chapman Steven Leonard CEO AND PRESIDENT Apr 29 '24 Sale 93.14 4,084 380,378 226,235 May 01 09:05 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Apr 29 '24 Sale 93.14 1,238 115,306 69,408 May 01 09:05 PM Sheena Jonathan CO-FOUNDER Apr 25 '24 Sale 89.55 1,000 89,550 69,082 Apr 26 09:35 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Apr 24 '24 Sale 93.00 937 87,140 72,102 Apr 26 09:35 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Apr 26 '24 Sale 92.00 751 69,092 70,646 Apr 26 09:35 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Apr 25 '24 Sale 89.55 705 63,133 71,397 Apr 26 09:35 PM RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER Apr 23 '24 Sale 91.38 787 71,915 205,552 Apr 23 09:35 PM Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS Apr 23 '24 Sale 91.38 531 48,522 117,029 Apr 23 09:35 PM Fesko John PRESIDENT, CHIEF BUS. OFFICER Apr 23 '24 Sale 91.38 522 47,700 111,677 Apr 23 09:35 PM Chapman Steven Leonard CEO AND PRESIDENT Apr 23 '24 Sale 91.38 2,552 233,200 230,319 Apr 23 09:35 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Apr 23 '24 Sale 91.38 1,523 139,171 73,039 Apr 23 09:35 PM Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS Apr 16 '24 Sale 90.82 80,000 7,265,651 117,560 Apr 17 09:05 PM Chapman Steven Leonard CEO AND PRESIDENT Apr 15 '24 Sale 93.13 6,816 634,797 227,710 Apr 17 09:05 PM Sheena Jonathan CO-FOUNDER Apr 03 '24 Sale 92.47 26,700 2,468,822 321,031 Apr 04 09:35 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Apr 02 '24 Sale 92.62 1,378 127,629 70,646 Apr 04 09:35 PM Sheena Jonathan CO-FOUNDER Mar 28 '24 Sale 90.13 1,000 90,130 69,582 Mar 29 09:35 PM Sheena Jonathan CO-FOUNDER Mar 28 '24 Sale 90.22 447 40,326 347,731 Mar 29 09:35 PM RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER Mar 28 '24 Sale 90.42 743 67,179 204,839 Mar 29 09:35 PM Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS Mar 28 '24 Sale 90.42 707 63,924 197,560 Mar 29 09:35 PM Fesko John PRESIDENT, CHIEF BUS. OFFICER Mar 28 '24 Sale 90.42 464 41,953 112,199 Mar 29 09:35 PM Chapman Steven Leonard CEO AND PRESIDENT Mar 15 '24 Sale 89.02 50,910 4,532,065 0 Mar 29 09:35 PM Chapman Steven Leonard CEO AND PRESIDENT Mar 28 '24 Sale 90.42 2,662 240,687 234,526 Mar 29 09:35 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Mar 28 '24 Sale 90.42 914 82,640 72,024 Mar 29 09:35 PM BOTHA ROELOF Director Mar 15 '24 Option Exercise 42.17 19,924 840,197 20,276 Mar 15 09:05 PM Chapman Steven Leonard CEO AND PRESIDENT Mar 15 '24 Option Exercise 19.37 68,270 1,322,406 315,227 Mar 15 09:05 PM Chapman Steven Leonard CEO AND PRESIDENT Mar 15 '24 Sale 88.96 83,223 7,403,534 232,004 Mar 15 09:05 PM Sheena Jonathan CO-FOUNDER Mar 06 '24 Sale 88.70 5,000 443,492 458,585 Mar 07 09:40 PM Sheena Jonathan CO-FOUNDER Mar 05 '24 Sale 88.36 1,028 90,839 463,585 Mar 07 09:40 PM RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER Mar 05 '24 Sale 88.36 2,160 190,868 204,218 Mar 07 09:40 PM Chapman Steven Leonard CEO AND PRESIDENT Mar 05 '24 Sale 88.36 9,326 824,092 246,957 Mar 07 09:40 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Mar 05 '24 Sale 88.36 2,826 249,719 70,646 Mar 07 09:40 PM Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS Mar 05 '24 Sale 88.36 2,245 198,361 198,267 Mar 07 09:40 PM Fesko John PRESIDENT, CHIEF BUS. OFFICER Mar 05 '24 Sale 88.36 1,838 162,400 112,663 Mar 07 09:40 PM Rabinowitz Matthew EXECUTIVE CHAIRMAN Mar 05 '24 Sale 87.40 190,000 16,605,069 860,036 Mar 07 09:40 PM Rabinowitz Matthew EXECUTIVE CHAIRMAN Mar 05 '24 Sale 88.36 1,012 89,416 1,075,648 Mar 07 09:40 PM Sheena Jonathan CO-FOUNDER Feb 29 '24 Sale 86.34 10,000 863,433 463,585 Mar 01 08:45 PM Sheena Jonathan CO-FOUNDER Feb 29 '24 Sale 90.02 6,000 540,109 14,655 Mar 01 08:45 PM RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER Feb 27 '24 Option Exercise 10.16 35,307 358,802 239,525 Feb 29 09:15 PM RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER Feb 29 '24 Option Exercise 9.29 20,526 190,687 224,744 Feb 29 09:15 PM RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER Feb 27 '24 Sale 75.09 35,307 2,651,298 204,218 Feb 29 09:15 PM RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER Feb 29 '24 Sale 89.01 20,526 1,826,970 204,218 Feb 29 09:15 PM Rabinowitz Matthew EXECUTIVE CHAIRMAN Feb 23 '24 Option Exercise 2.66 380,036 1,009,718 1,050,036 Feb 23 09:40 PM ROSENMAN HERM Director Feb 16 '24 Option Exercise 2.66 93,901 249,486 155,586 Feb 16 09:45 PM ROSENMAN HERM Director Feb 16 '24 Sale 69.37 93,901 6,514,371 61,685 Feb 16 09:45 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Feb 06 '24 Option Exercise 16.61 34,029 565,063 104,675 Feb 08 09:40 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Feb 06 '24 Sale 70.03 34,029 2,383,129 70,646 Feb 08 09:40 PM Sheena Jonathan CO-FOUNDER Feb 06 '24 Sale 70.00 6,000 420,011 18,155 Feb 08 09:05 PM Sheena Jonathan CO-FOUNDER Feb 07 '24 Sale 70.10 5,000 350,486 473,585 Feb 08 09:05 PM Sheena Jonathan CO-FOUNDER Feb 07 '24 Sale 70.10 1,000 70,099 17,655 Feb 08 09:05 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Feb 01 '24 Sale 67.73 22,281 1,509,081 70,646 Feb 02 09:40 PM Brophy Michael Burkes CHIEF FINANCIAL OFFICER Jan 29 '24 Sale 65.09 3,235 210,570 92,927 Jan 30 09:15 PM Sheena Jonathan CO-FOUNDER Jan 29 '24 Sale 65.09 546 35,540 478,585 Jan 30 09:05 PM RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER Jan 29 '24 Sale 65.09 4,265 277,614 204,218 Jan 30 09:05 PM Chapman Steven Leonard CEO AND PRESIDENT Jan 29 '24 Sale 65.09 14,813 964,194 246,957 Jan 30 09:05 PM
Index RUT
P/E -
EPS (ttm) -0.74
Insider Own 1.51%
Shs Outstand 76.81M
Perf Week -10.55%
Market Cap 2.19B
Forward P/E 70.74
EPS next Y 0.40
Insider Trans -7.99%
Shs Float 75.63M
Perf Month 5.62%
Income -54.04M
PEG -
EPS next Q 0.04
Inst Own 103.39%
Short Float 4.11%
Perf Quarter 33.44%
Sales 399.58M
P/S 5.49
EPS this Y 120.76%
Inst Trans 0.34%
Short Ratio 3.30
Perf Half Y 25.58%
Book/sh 14.76
P/B 1.94
EPS next Y 90.71%
ROA -4.51%
Short Interest 3.11M
Perf Year 9.84%
Cash/sh 3.07
P/C 9.30
EPS next 5Y -
ROE -4.88%
52W Range 18.61 - 33.33
Perf YTD 3.85%
Dividend Est. -
P/FCF 54.68
EPS past 5Y -10.52%
ROI -4.72%
52W High -14.28%
Beta 1.66
Dividend TTM -
Quick Ratio 4.17
Sales past 5Y 34.42%
Gross Margin 63.87%
52W Low 53.52%
ATR (14) 1.31
Dividend Ex-Date -
Current Ratio 4.44
EPS Y/Y TTM -84.43%
Oper. Margin 1.86%
RSI (14) 46.43
Volatility 3.97% 4.11%
Employees 815
Debt/Eq 0.02
Sales Y/Y TTM 21.59%
Profit Margin -13.52%
Recom 1.80
Target Price 34.57
Option/Short Yes / Yes
LT Debt/Eq 0.01
EPS Q/Q 164.11%
Payout -
Rel Volume 0.86
Prev Close 29.77
Sales Surprise 14.09%
EPS Surprise 526.83%
Sales Q/Q 26.69%
Earnings Aug 06 AMC
Avg Volume 941.31K
Price 28.57
SMA20 -8.75%
SMA50 8.95%
SMA200 18.23%
Trades
Volume 810,969
Change -4.03%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-23-24 Reiterated
Needham
Buy
$30 → $33
Jan-18-23 Downgrade
Raymond James
Outperform → Mkt Perform
Jan-05-23 Initiated
Scotiabank
Sector Outperform
$33
Jan-07-22 Initiated
Stephens
Overweight
$52
Nov-18-21 Resumed
Goldman
Buy
$60
Jun-15-21 Initiated
Raymond James
Outperform
$45
Feb-18-21 Resumed
Needham
Buy
$88
Jan-28-21 Initiated
Truist
Buy
$61
Nov-10-20 Initiated
KeyBanc Capital Markets
Sector Weight
$48
Sep-09-20 Initiated
Morgan Stanley
Underweight
$35
Jul-31-19 Initiated
Lake Street
Buy
$35
Jul-02-19 Initiated
Needham
Buy
$33
Nov-29-18 Downgrade
Janney
Buy → Neutral
Oct-31-18 Upgrade
Janney
Neutral → Buy
Nov-07-17 Downgrade
Piper Jaffray
Overweight → Neutral
Nov-07-17 Downgrade
Janney
Buy → Neutral
Aug-31-17 Resumed
BTIG Research
Buy
$13
Nov-14-16 Resumed
Leerink Partners
Outperform
$12
Dec-18-15 Initiated
Cantor Fitzgerald
Buy
$13
Jun-11-15 Reiterated
Leerink Partners
Outperform
$11 → $13
Show Previous Ratings
Sep-06-24 07:01PM
Sep-05-24 11:31AM
Sep-04-24 04:05PM
09:50AM
Aug-26-24 05:30PM
09:00AM
Loading…
09:00AM
04:36AM
Aug-19-24 09:55AM
Aug-15-24 09:50AM
Aug-14-24 09:15AM
Aug-09-24 07:22PM
Aug-08-24 09:09AM
Aug-07-24 02:08PM
Aug-06-24 06:25PM
05:24PM
(Associated Press Finance)
04:05PM
Loading…
04:05PM
Jul-24-24 10:57AM
Jul-19-24 12:01AM
Jul-17-24 05:00PM
04:48AM
Jun-21-24 09:55AM
Jun-06-24 11:31AM
Jun-03-24 04:05PM
May-29-24 09:55AM
09:30AM
May-28-24 09:31AM
08:47AM
08:32AM
May-23-24 10:00AM
May-22-24 04:05PM
09:59AM
Loading…
May-21-24 09:59AM
May-15-24 05:04PM
May-13-24 09:55AM
May-08-24 03:13PM
08:55AM
07:12AM
(Thomson Reuters StreetEvents)
03:48AM
May-07-24 10:55PM
06:13PM
(Associated Press Finance)
06:00PM
04:05PM
May-06-24 04:05PM
Apr-22-24 05:00PM
08:30AM
Apr-16-24 08:30AM
Apr-02-24 10:33AM
Feb-27-24 05:55PM
Feb-26-24 03:20PM
Feb-23-24 11:10AM
07:43AM
07:37AM
(Thomson Reuters StreetEvents)
Feb-22-24 06:05PM
05:03PM
(Associated Press Finance)
04:40PM
04:05PM
Feb-21-24 05:00PM
Feb-08-24 08:00AM
Feb-06-24 08:15AM
Jan-08-24 08:00AM
Dec-12-23 04:30PM
Dec-01-23 04:05PM
Nov-29-23 08:30AM
Nov-22-23 08:30AM
Nov-08-23 04:39PM
Nov-07-23 04:57PM
(Associated Press Finance)
04:05PM
04:00PM
Nov-02-23 08:15AM
Oct-27-23 08:30AM
Oct-26-23 02:50PM
Oct-17-23 08:15AM
Oct-16-23 10:43AM
Oct-12-23 09:00AM
Oct-04-23 04:05PM
Sep-28-23 04:05PM
08:15AM
Sep-27-23 09:00AM
Sep-21-23 04:05PM
Sep-07-23 04:05PM
Sep-06-23 08:15AM
Sep-02-23 06:15AM
Aug-29-23 08:15AM
Aug-22-23 08:15AM
Aug-15-23 04:15PM
Aug-08-23 06:05PM
04:55PM
04:05PM
Aug-01-23 08:15AM
Jul-19-23 05:00PM
Jul-08-23 08:43PM
Jun-20-23 08:31AM
Jun-12-23 08:31AM
May-30-23 06:56AM
May-25-23 05:13PM
May-24-23 09:00AM
May-23-23 05:00PM
May-22-23 07:30AM
May-12-23 06:15AM
May-05-23 01:59PM
May-04-23 06:25PM
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Leite John Chief Commercial Officer-CLIA Sep 04 '24 Sale 29.78 5,479 163,159 76,174 Sep 06 04:18 PM JOHN LEITE Officer Sep 04 '24 Proposed Sale 30.29 5,479 165,959 Sep 04 04:17 PM JONES EVAN/ FA Director Aug 13 '24 Option Exercise 10.41 8,486 88,339 54,800 Aug 14 05:09 PM JONES EVAN/ FA Director Aug 13 '24 Sale 32.20 27,188 875,565 5,173 Aug 14 05:09 PM JONES EVAN/ FA Director Aug 13 '24 Sale 32.20 20,457 658,801 34,343 Aug 14 05:09 PM JONES EVAN/ FA Director Aug 12 '24 Sale 30.00 101 3,031 32,361 Aug 14 05:09 PM JONES EVAN/ FA Director Aug 12 '24 Sale 30.01 99 2,971 46,314 Aug 14 05:09 PM JONES EVAN/ FA Director Aug 09 '24 Option Exercise 10.41 300 3,123 47,445 Aug 13 04:38 PM JONES EVAN/ FA Director Aug 09 '24 Sale 30.03 1,032 30,990 46,413 Aug 13 04:38 PM JONES EVAN/ FA Director Aug 09 '24 Sale 30.03 746 22,402 32,462 Aug 13 04:38 PM Holstein Jens Director Aug 07 '24 Sale 29.00 5,000 145,000 27,878 Aug 09 04:47 PM JONES EVAN/ FA Director Aug 07 '24 Option Exercise 10.41 1,214 12,638 50,288 Aug 09 04:47 PM JONES EVAN/ FA Director Aug 07 '24 Sale 30.32 5,108 154,883 45,180 Aug 09 04:47 PM Evan Jones Director Aug 07 '24 Proposed Sale 27.05 59,904 1,620,403 Aug 07 07:52 PM EASTHAM KARIN Director Jul 16 '24 Sale 25.00 7,500 187,500 33,228 Jul 18 06:25 PM Leite John Chief Commercial Officer-CLIA Jul 16 '24 Sale 25.00 1,277 31,925 82,968 Jul 18 06:25 PM Holstein Jens Director Jul 16 '24 Sale 24.50 5,000 122,500 32,878 Jul 18 06:25 PM EASTHAM KARIN Director Jun 11 '24 Sale 20.59 3,870 79,683 29,255 Jun 13 04:24 PM Bhanji Muna Director Jun 10 '24 Sale 20.32 3,870 78,634 23,105 Jun 11 04:22 PM EASTHAM KARIN Director Jun 07 '24 Option Exercise 10.41 2,500 26,025 35,625 Jun 11 04:21 PM EASTHAM KARIN Director Jun 07 '24 Sale 20.97 2,500 52,425 33,125 Jun 11 04:21 PM Bhanji Muna Director May 28 '24 Sale 21.00 1,539 32,319 26,975 May 30 04:41 PM EASTHAM KARIN Director Apr 01 '24 Option Exercise 13.19 10,000 131,900 43,125 Apr 02 04:17 PM EASTHAM KARIN Director Apr 01 '24 Sale 21.65 10,000 216,528 33,125 Apr 02 04:17 PM JONES EVAN/ FA Director Mar 01 '24 Option Exercise 13.19 10,000 131,900 47,601 Mar 05 05:28 PM JONES EVAN/ FA Director Mar 01 '24 Sale 24.36 10,000 243,599 37,601 Mar 05 05:28 PM
Index RUT
P/E -
EPS (ttm) -0.13
Insider Own 6.53%
Shs Outstand 27.41M
Perf Week -1.58%
Market Cap 813.34M
Forward P/E -
EPS next Y -2.32
Insider Trans -7.30%
Shs Float 25.93M
Perf Month 9.36%
Income -3.10M
PEG -
EPS next Q -0.03
Inst Own 87.93%
Short Float 6.56%
Perf Quarter 27.31%
Sales 287.59M
P/S 2.83
EPS this Y 72.71%
Inst Trans -2.01%
Short Ratio 4.17
Perf Half Y 41.30%
Book/sh 15.30
P/B 1.92
EPS next Y -296.71%
ROA -0.68%
Short Interest 1.70M
Perf Year 53.67%
Cash/sh 9.36
P/C 3.13
EPS next 5Y -
ROE -0.77%
52W Range 12.07 - 30.50
Perf YTD 35.87%
Dividend Est. -
P/FCF 31.75
EPS past 5Y -28.57%
ROI -0.69%
52W High -3.87%
Beta 1.03
Dividend TTM -
Quick Ratio 7.92
Sales past 5Y 60.93%
Gross Margin 78.13%
52W Low 142.92%
ATR (14) 1.52
Dividend Ex-Date -
Current Ratio 8.12
EPS Y/Y TTM 96.35%
Oper. Margin -5.48%
RSI (14) 61.81
Volatility 4.50% 5.12%
Employees 610
Debt/Eq 0.06
Sales Y/Y TTM 71.67%
Profit Margin -1.08%
Recom 1.11
Target Price 35.56
Option/Short Yes / Yes
LT Debt/Eq 0.06
EPS Q/Q 144.19%
Payout -
Rel Volume 0.74
Prev Close 29.48
Sales Surprise 24.90%
EPS Surprise 215.37%
Sales Q/Q 73.53%
Earnings Aug 05 AMC
Avg Volume 408.43K
Price 29.32
SMA20 3.96%
SMA50 23.68%
SMA200 31.99%
Trades
Volume 302,921
Change -0.54%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-14-23 Initiated
Guggenheim
Buy
$25
Jan-05-23 Initiated
Scotiabank
Sector Outperform
$54
Jan-07-22 Initiated
Stephens
Overweight
$59
Apr-30-21 Initiated
Lake Street
Buy
$94
Nov-10-20 Initiated
KeyBanc Capital Markets
Overweight
$70
Dec-27-19 Reiterated
Canaccord Genuity
Buy
$34 → $35
Aug-19-19 Initiated
SVB Leerink
Outperform
$28
Aug-19-19 Initiated
Robert W. Baird
Outperform
$27
Aug-19-19 Initiated
Canaccord Genuity
Buy
$26
Aug-19-19 Initiated
BTIG Research
Buy
$25
Sep-05-24 07:02PM
07:00AM
Aug-28-24 07:00AM
Aug-05-24 05:45PM
04:05PM
07:00AM
Loading…
Jul-30-24 07:00AM
Jul-29-24 10:00AM
Jul-22-24 07:00AM
Jul-15-24 07:00AM
Jul-12-24 12:00PM
Jul-11-24 07:00AM
Jun-24-24 07:00AM
Jun-20-24 07:00AM
Jun-14-24 04:30PM
Jun-13-24 09:40AM
04:30PM
Loading…
May-30-24 04:30PM
May-29-24 04:30PM
May-23-24 09:55AM
08:50AM
May-15-24 07:00AM
May-14-24 07:00AM
May-10-24 07:00AM
May-08-24 05:22PM
04:30PM
May-07-24 09:55AM
May-06-24 08:50AM
May-05-24 08:32AM
May-03-24 07:00AM
May-02-24 08:56PM
05:59PM
05:50PM
Loading…
05:50PM
04:05PM
Apr-30-24 04:30PM
Apr-11-24 07:00AM
Apr-10-24 05:00PM
07:00AM
Apr-05-24 04:43AM
Apr-04-24 04:30PM
Apr-02-24 07:00AM
Mar-27-24 05:00PM
Mar-25-24 07:00AM
Mar-22-24 04:30PM
Mar-20-24 05:17AM
Mar-19-24 07:00AM
Mar-15-24 04:30PM
Mar-12-24 07:00AM
Mar-08-24 04:30PM
Mar-07-24 07:00AM
Feb-29-24 10:37AM
08:43AM
(Thomson Reuters StreetEvents)
Feb-28-24 06:30PM
05:40PM
04:42PM
04:05PM
Feb-26-24 09:16AM
07:00AM
Feb-07-24 07:00AM
Jan-18-24 07:00AM
Jan-14-24 04:30AM
Jan-09-24 07:00AM
Jan-07-24 08:00PM
Dec-20-23 07:00AM
Dec-12-23 09:55AM
Dec-01-23 07:00AM
Nov-14-23 07:00AM
Nov-13-23 07:00AM
Nov-08-23 04:30PM
01:00PM
Nov-04-23 09:18AM
Nov-03-23 08:11AM
(Thomson Reuters StreetEvents) +7.99%
07:00AM
Nov-02-23 07:30PM
07:24PM
04:06PM
04:05PM
Oct-24-23 07:00AM
Oct-19-23 07:00AM
Oct-18-23 04:30PM
Oct-05-23 07:00AM
Oct-03-23 07:00AM
Oct-02-23 07:00AM
Sep-25-23 07:00AM
Sep-19-23 07:00AM
Sep-14-23 07:00AM
Sep-12-23 07:00AM
Sep-09-23 08:00PM
Sep-08-23 04:30PM
Sep-06-23 07:00AM
Sep-05-23 07:00AM
Aug-07-23 07:00AM
Aug-03-23 11:17AM
08:31AM
Aug-02-23 07:30PM
06:15PM
04:05PM
Aug-01-23 07:00AM
Jul-26-23 10:02AM
Jul-19-23 07:00AM
Jul-18-23 07:00AM
Jul-17-23 07:00AM
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MAETZOLD DEREK J Pres. & Chief Exec. Officer Sep 03 '24 Sale 30.05 699 21,004 8,005 Sep 05 04:07 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Sep 04 '24 Sale 30.02 500 15,012 7,956 Sep 05 04:07 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Sep 03 '24 Sale 30.05 417 12,530 99,870 Sep 05 04:07 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Sep 04 '24 Sale 30.02 298 8,947 99,572 Sep 05 04:07 PM Oelschlager Kristen M Chief Operating Officer Sep 03 '24 Sale 29.21 5,832 170,330 134,841 Sep 05 04:06 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Aug 29 '24 Sale 30.07 2,246 67,548 8,126 Sep 03 04:08 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Aug 29 '24 Sale 30.07 1,334 40,120 100,609 Sep 03 04:08 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Aug 30 '24 Sale 30.10 539 16,223 8,073 Sep 03 04:08 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Aug 30 '24 Sale 30.10 322 9,692 100,287 Sep 03 04:08 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Aug 23 '24 Sale 30.09 1,746 52,535 8,356 Aug 27 04:11 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Aug 23 '24 Sale 30.09 1,037 31,202 102,019 Aug 27 04:11 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Aug 26 '24 Sale 30.05 128 3,846 8,342 Aug 27 04:11 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Aug 26 '24 Sale 30.05 76 2,284 101,943 Aug 27 04:11 PM Derek Maetzold Officer Aug 23 '24 Proposed Sale 29.57 44,380 1,312,317 Aug 23 05:17 PM BRADBURY DANIEL Director Aug 12 '24 Sale 26.65 7,883 210,058 8,550 Aug 14 04:53 PM Stokes Frank Chief Financial Officer Aug 07 '24 Sale 25.70 10,000 256,997 30,823 Aug 13 06:13 PM Daniel Bradbury Officer Aug 12 '24 Proposed Sale 26.75 15,750 421,312 Aug 12 04:37 PM Oelschlager Kristen M Chief Operating Officer Aug 01 '24 Sale 23.06 12,989 299,503 132,836 Aug 05 04:16 PM Stokes Frank Officer Aug 07 '24 Proposed Sale 20.92 10,000 209,200 Aug 02 03:13 PM Oelschlager Kristen M Chief Operating Officer Jul 29 '24 Sale 22.06 2,793 61,622 145,825 Jul 31 04:50 PM Oelschlager Kristen M Chief Operating Officer Jul 01 '24 Sale 21.22 2,793 59,279 148,618 Jul 03 04:15 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Jun 03 '24 Sale 23.40 3,968 92,857 8,525 Jun 05 05:23 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Jun 03 '24 Sale 23.40 2,368 55,416 57,893 Jun 05 05:23 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer May 14 '24 Sale 24.27 3,968 96,290 8,911 May 16 04:20 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer May 14 '24 Sale 24.27 2,368 57,463 60,261 May 16 04:20 PM BRADBURY DANIEL Director May 06 '24 Sale 24.64 23,323 574,679 9,981 May 08 04:51 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer May 06 '24 Sale 24.72 3,968 98,089 9,297 May 08 04:47 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer May 06 '24 Sale 24.72 2,368 58,537 62,629 May 08 04:47 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Apr 23 '24 Sale 20.11 705 14,177 9,683 Apr 25 04:54 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Apr 23 '24 Sale 20.11 421 8,466 64,997 Apr 25 04:54 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Apr 12 '24 Sale 20.35 3,263 66,402 9,752 Apr 16 04:46 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Apr 12 '24 Sale 20.35 1,947 39,621 65,418 Apr 16 04:46 PM BRADBURY DANIEL Director Apr 08 '24 Sale 20.45 2,400 49,087 17,944 Apr 10 04:35 PM BRADBURY DANIEL Director Apr 05 '24 Sale 20.86 11,771 245,543 18,763 Apr 08 04:31 PM BRADBURY DANIEL Director Apr 04 '24 Sale 21.45 9,152 196,310 22,782 Apr 08 04:31 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Apr 03 '24 Sale 21.70 3,968 86,106 10,069 Apr 05 04:37 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Apr 03 '24 Sale 21.70 2,368 51,386 67,365 Apr 05 04:37 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Mar 20 '24 Sale 20.27 3,847 77,979 10,467 Mar 22 05:16 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Mar 20 '24 Sale 20.27 2,295 46,520 69,806 Mar 22 05:16 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Mar 21 '24 Sale 20.70 121 2,505 10,455 Mar 22 05:16 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Mar 21 '24 Sale 20.70 73 1,511 69,733 Mar 22 05:16 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Mar 07 '24 Sale 20.77 3,996 82,997 10,841 Mar 11 05:18 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Mar 07 '24 Sale 20.77 2,372 49,266 72,101 Mar 11 05:18 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Mar 05 '24 Option Exercise 3.72 10,686 39,752 78,604 Mar 06 05:58 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Mar 05 '24 Sale 21.41 4,131 88,461 74,473 Mar 06 05:58 PM BRADBURY DANIEL Director Mar 04 '24 Sale 20.68 23,323 482,285 25,907 Mar 06 05:52 PM BRADBURY DANIEL Director Feb 07 '24 Sale 23.20 2,074 48,117 33,870 Feb 09 04:49 PM BRADBURY DANIEL Director Feb 05 '24 Sale 22.90 11,402 261,134 37,940 Feb 07 04:19 PM BRADBURY DANIEL Director Feb 06 '24 Sale 23.63 9,847 232,685 34,578 Feb 07 04:19 PM BRADBURY DANIEL Director Jan 04 '24 Sale 20.40 18,223 371,749 43,574 Jan 08 04:19 PM BRADBURY DANIEL Director Jan 05 '24 Sale 20.36 5,100 103,836 41,833 Jan 08 04:19 PM Juvenal Tobin W Chief Commercial Officer Jan 02 '24 Option Exercise 2.89 6,701 19,381 46,857 Jan 04 05:16 PM Oelschlager Kristen M Chief Operating Officer Dec 29 '23 Option Exercise 3.01 12,615 38,034 150,302 Jan 03 04:11 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 27 '23 Sale 21.90 8,076 176,864 68,038 Dec 29 04:05 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 28 '23 Sale 22.17 3,954 87,660 64,084 Dec 29 04:05 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 27 '23 Sale 21.90 1,137 24,900 11,688 Dec 29 04:05 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 28 '23 Sale 22.17 557 12,349 11,629 Dec 29 04:05 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 22 '23 Sale 21.96 5,224 114,719 81,294 Dec 27 04:18 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 26 '23 Sale 21.93 5,180 113,597 76,114 Dec 27 04:18 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 22 '23 Sale 21.96 736 16,163 11,884 Dec 27 04:18 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 26 '23 Sale 21.93 729 15,987 11,807 Dec 27 04:18 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 21 '23 Sale 21.40 10,999 235,412 86,518 Dec 22 04:06 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 20 '23 Sale 21.05 5,201 109,455 97,517 Dec 22 04:06 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 21 '23 Sale 21.40 1,549 33,153 11,962 Dec 22 04:06 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 20 '23 Sale 21.05 733 15,426 12,125 Dec 22 04:06 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 19 '23 Sale 20.84 5,719 119,161 102,718 Dec 20 04:46 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 18 '23 Sale 20.27 5,720 115,962 108,437 Dec 20 04:46 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 19 '23 Sale 20.84 3,314 69,051 12,202 Dec 20 04:46 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 18 '23 Sale 20.27 1,498 30,369 12,552 Dec 20 04:46 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 14 '23 Sale 20.89 9,976 208,363 12,827 Dec 18 04:06 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 14 '23 Sale 20.89 9,152 191,151 117,866 Dec 18 04:06 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 15 '23 Sale 20.21 3,709 74,959 114,157 Dec 18 04:06 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 15 '23 Sale 20.21 1,113 22,494 12,710 Dec 18 04:06 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 13 '23 Sale 20.21 3,980 80,436 13,879 Dec 14 05:39 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 13 '23 Sale 20.21 3,652 73,807 127,018 Dec 14 05:39 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 12 '23 Sale 20.01 546 10,925 130,670 Dec 14 05:39 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 12 '23 Sale 20.01 254 5,083 14,298 Dec 14 05:39 PM BRADBURY DANIEL Director Dec 12 '23 Sale 20.01 1,200 24,012 50,195 Dec 14 05:32 PM BRADBURY DANIEL Director Dec 13 '23 Sale 20.04 1,168 23,407 49,796 Dec 14 05:32 PM Oelschlager Kristen M Chief Operating Officer Dec 10 '23 Option Exercise 0.00 7,920 0 138,149 Dec 12 07:39 PM Oelschlager Kristen M Chief Operating Officer Dec 09 '23 Option Exercise 0.00 15,961 0 136,061 Dec 12 07:39 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 10 '23 Option Exercise 0.00 20,787 0 133,327 Dec 12 07:23 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 09 '23 Option Exercise 0.00 33,496 0 128,391 Dec 12 07:23 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 08 '23 Sale 20.10 2,530 50,853 14,325 Dec 12 07:23 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 08 '23 Sale 20.10 2,322 46,672 94,895 Dec 12 07:23 PM BRADBURY DANIEL Director Dec 08 '23 Sale 20.09 6,875 138,119 50,605 Dec 12 07:19 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 06 '23 Sale 20.02 52 1,041 14,592 Dec 08 04:38 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 06 '23 Sale 20.02 48 961 97,217 Dec 08 04:38 PM BRADBURY DANIEL Director Dec 06 '23 Sale 20.02 200 4,004 52,952 Dec 08 04:35 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 01 '23 Sale 20.06 3,526 70,732 14,756 Dec 05 05:49 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 01 '23 Sale 20.06 3,235 64,894 98,644 Dec 05 05:49 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 04 '23 Sale 20.08 1,504 30,200 14,597 Dec 05 05:49 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Dec 04 '23 Sale 20.08 1,379 27,690 97,265 Dec 05 05:49 PM BRADBURY DANIEL Director Dec 01 '23 Sale 20.05 9,545 191,425 54,502 Dec 05 05:46 PM BRADBURY DANIEL Director Dec 04 '23 Sale 20.08 4,340 87,165 53,020 Dec 05 05:46 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Nov 29 '23 Sale 20.13 6,261 126,034 15,645 Dec 01 04:34 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Nov 29 '23 Sale 20.13 5,743 115,607 106,389 Dec 01 04:34 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Nov 30 '23 Sale 20.07 4,915 98,644 15,127 Dec 01 04:34 PM MAETZOLD DEREK J Pres. & Chief Exec. Officer Nov 30 '23 Sale 20.07 4,510 90,516 101,879 Dec 01 04:34 PM BRADBURY DANIEL Director Nov 29 '23 Sale 20.12 17,342 349,008 60,197 Dec 01 04:30 PM
Index RUT
P/E -
EPS (ttm) -2.74
Insider Own 18.78%
Shs Outstand 37.03M
Perf Week -6.52%
Market Cap 557.67M
Forward P/E -
EPS next Y -3.21
Insider Trans -0.02%
Shs Float 30.08M
Perf Month -6.17%
Income -82.59M
PEG -
EPS next Q -0.65
Inst Own 74.01%
Short Float 8.29%
Perf Quarter 4.95%
Sales 0.00M
P/S -
EPS this Y 4.09%
Inst Trans 4.81%
Short Ratio 6.65
Perf Half Y -16.05%
Book/sh 4.77
P/B 3.16
EPS next Y -24.27%
ROA -37.03%
Short Interest 2.49M
Perf Year 67.15%
Cash/sh 7.64
P/C 1.97
EPS next 5Y 29.00%
ROE -57.59%
52W Range 8.39 - 22.19
Perf YTD 3.36%
Dividend Est. -
P/FCF -
EPS past 5Y -29.52%
ROI -30.25%
52W High -32.13%
Beta 0.76
Dividend TTM -
Quick Ratio 14.95
Sales past 5Y 0.00%
Gross Margin -
52W Low 79.52%
ATR (14) 0.89
Dividend Ex-Date -
Current Ratio 14.95
EPS Y/Y TTM -4.32%
Oper. Margin 0.00%
RSI (14) 36.26
Volatility 4.35% 6.08%
Employees 55
Debt/Eq 0.55
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 28.57
Option/Short Yes / Yes
LT Debt/Eq 0.55
EPS Q/Q 7.13%
Payout -
Rel Volume 0.40
Prev Close 15.69
Sales Surprise -
EPS Surprise 8.64%
Sales Q/Q -
Earnings Aug 14 AMC
Avg Volume 375.32K
Price 15.06
SMA20 -8.34%
SMA50 -11.51%
SMA200 -7.28%
Trades
Volume 149,180
Change -4.02%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-22-24 Initiated
Leerink Partners
Outperform
$29
Feb-22-24 Initiated
Stifel
Buy
$40
Dec-08-23 Initiated
H.C. Wainwright
Buy
$27
Oct-08-21 Initiated
Canaccord Genuity
Buy
$50
Sep-07-21 Initiated
Jefferies
Buy
$48
Jul-29-21 Initiated
Cowen
Outperform
Jul-27-21 Initiated
Needham
Buy
$50
Jan-28-21 Reiterated
H.C. Wainwright
Buy
$14 → $18
Dec-24-20 Reiterated
H.C. Wainwright
Buy
$11 → $14
May-11-20 Resumed
Craig Hallum
Buy
Nov-20-18 Initiated
H.C. Wainwright
Buy
$36
Show Previous Ratings
Aug-20-24 12:00PM
Aug-14-24 04:01PM
Aug-07-24 07:05AM
Jun-03-24 04:01PM
May-30-24 07:36AM
07:00AM
Loading…
07:00AM
May-16-24 11:54AM
03:08AM
May-15-24 08:55PM
06:04PM
04:01PM
May-08-24 07:05AM
May-03-24 12:15PM
Apr-04-24 07:05AM
Apr-01-24 01:38PM
06:51AM
Loading…
Mar-28-24 06:51AM
(Thomson Reuters StreetEvents) +18.94%
Mar-27-24 08:53PM
05:51PM
04:01PM
Mar-21-24 11:17AM
Mar-20-24 07:05AM
Mar-06-24 07:05AM
Feb-28-24 07:05AM
Feb-22-24 04:05PM
Feb-20-24 07:05AM
Dec-06-23 08:30AM
Dec-01-23 11:02AM
Nov-22-23 08:05AM
Nov-14-23 10:50AM
Nov-13-23 09:41PM
(Thomson Reuters StreetEvents)
10:54AM
Loading…
10:54AM
07:05AM
Nov-06-23 07:30AM
Nov-01-23 07:05AM
Oct-18-23 09:15AM
Sep-21-23 04:43PM
Sep-07-23 04:05PM
Sep-06-23 07:10PM
Aug-22-23 04:05PM
04:01PM
Aug-11-23 05:58AM
(Thomson Reuters StreetEvents)
Aug-10-23 04:04PM
Aug-03-23 07:30AM
Jul-31-23 08:00AM
Jul-27-23 06:51AM
Jun-20-23 09:02AM
May-24-23 08:00AM
07:59AM
May-16-23 06:26AM
(Thomson Reuters StreetEvents)
May-15-23 04:00PM
May-12-23 06:15AM
May-08-23 05:30PM
08:00AM
Apr-18-23 01:30PM
Apr-12-23 08:00AM
Mar-27-23 02:43AM
Mar-24-23 07:07AM
(Thomson Reuters StreetEvents) -5.47%
Mar-23-23 04:00PM
Mar-16-23 08:00AM
Mar-15-23 07:35PM
Mar-01-23 08:00AM
Feb-17-23 05:07AM
Feb-16-23 08:00AM
Dec-18-22 04:38AM
Dec-15-22 05:59AM
Dec-12-22 07:30AM
Dec-09-22 08:40AM
Dec-07-22 04:00PM
(ACCESSWIRE) -6.21%
+26.36%
Nov-22-22 07:30AM
Nov-10-22 04:30PM
04:00PM
Nov-03-22 08:50AM
Sep-14-22 09:00AM
Aug-15-22 09:39AM
Aug-11-22 04:00PM
Aug-04-22 08:15AM
Aug-03-22 10:15AM
Jul-18-22 06:31PM
05:10PM
Jun-15-22 09:55AM
May-30-22 09:55AM
May-26-22 07:30AM
May-16-22 04:00PM
07:00AM
May-11-22 09:28AM
(Simply Wall St.) -17.53%
May-09-22 07:30AM
Apr-05-22 07:30AM
Mar-23-22 04:00PM
Mar-16-22 07:30AM
Mar-02-22 07:30AM
Mar-01-22 07:02AM
Jan-18-22 12:39PM
07:30AM
Dec-10-21 09:30AM
Dec-02-21 08:30AM
Nov-29-21 05:00PM
Nov-15-21 08:00AM
Nov-09-21 05:30PM
Nov-08-21 04:00PM
Oct-29-21 09:00AM
Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Buller Richard E Director Aug 23 '24 Sale 16.95 350 5,932 7,031 Aug 27 04:13 PM Buller Richard E Director Aug 23 '24 Proposed Sale 16.95 700 11,865 Aug 23 10:27 AM Buller Richard E Director Jun 21 '24 Sale 15.68 350 5,488 7,381 Jun 25 04:19 PM Buller Richard E Director Apr 24 '24 Sale 17.06 350 5,971 7,731 Apr 26 04:55 PM Buller Richard E Director Feb 21 '24 Sale 14.15 350 4,952 8,081 Feb 23 04:43 PM Buller Richard E Director Dec 20 '23 Sale 14.37 350 5,030 8,431 Dec 22 04:09 PM Dalvey David Director Dec 14 '23 Sale 14.75 5,000 73,752 227,940 Dec 18 04:43 PM Dalvey David Director Dec 15 '23 Sale 14.57 2,940 42,847 225,000 Dec 18 04:43 PM Dalvey David Director Dec 13 '23 Sale 14.50 5,000 72,500 232,940 Dec 14 06:05 PM Dalvey David Director Dec 12 '23 Sale 14.61 2,060 30,089 237,940 Dec 14 06:05 PM Dalvey David Director Dec 08 '23 Sale 15.00 5,000 75,000 240,000 Dec 11 04:19 PM Dalvey David Director Dec 07 '23 Sale 14.85 5,000 74,250 245,000 Dec 11 04:19 PM Furcht Leo Director Nov 28 '23 Option Exercise 1.60 250 400 10,500 Nov 30 04:12 PM Buller Richard E Director Oct 25 '23 Sale 10.23 350 3,580 8,781 Oct 27 04:30 PM
Index RUT
P/E 425.14
EPS (ttm) 0.15
Insider Own 13.83%
Shs Outstand 67.96M
Perf Week -3.52%
Market Cap 4.62B
Forward P/E 93.15
EPS next Y 0.67
Insider Trans -2.84%
Shs Float 63.73M
Perf Month 9.70%
Income 9.92M
PEG 28.34
EPS next Q 0.16
Inst Own 82.93%
Short Float 4.77%
Perf Quarter 2.11%
Sales 1.71B
P/S 2.69
EPS this Y 506.67%
Inst Trans 0.51%
Short Ratio 5.10
Perf Half Y 28.57%
Book/sh 11.91
P/B 5.24
EPS next Y 120.88%
ROA 0.33%
Short Interest 3.04M
Perf Year 101.71%
Cash/sh 10.03
P/C 6.22
EPS next 5Y 15.00%
ROE 1.35%
52W Range 25.11 - 66.57
Perf YTD 79.49%
Dividend Est. -
P/FCF 67.93
EPS past 5Y -41.06%
ROI 0.39%
52W High -6.25%
Beta 1.75
Dividend TTM -
Quick Ratio 2.12
Sales past 5Y 11.14%
Gross Margin 6.21%
52W Low 148.55%
ATR (14) 2.85
Dividend Ex-Date -
Current Ratio 2.12
EPS Y/Y TTM 165.79%
Oper. Margin 6.21%
RSI (14) 48.85
Volatility 6.14% 4.51%
Employees 7872
Debt/Eq 1.95
Sales Y/Y TTM 12.14%
Profit Margin 0.58%
Recom 1.33
Target Price 71.83
Option/Short Yes / Yes
LT Debt/Eq 1.86
EPS Q/Q -129.55%
Payout 0.00%
Rel Volume 1.40
Prev Close 63.19
Sales Surprise 4.83%
EPS Surprise -123.63%
Sales Q/Q 13.87%
Earnings Aug 08 BMO
Avg Volume 596.37K
Price 62.41
SMA20 -1.89%
SMA50 1.59%
SMA200 27.60%
Trades
Volume 833,710
Change -1.23%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-06-24 Upgrade
Barclays
Equal Weight → Overweight
$57 → $79
Mar-06-24 Initiated
Barclays
Equal Weight
$48
Aug-31-23 Initiated
Truist
Buy
$40
Mar-31-23 Initiated
CJS Securities
Market Outperform
$30
Mar-03-23 Upgrade
Raymond James
Mkt Perform → Outperform
$30
Aug-12-21 Initiated
Barclays
Overweight
$39
Mar-15-19 Downgrade
Raymond James
Strong Buy → Outperform
$16 → $17.50
Mar-14-18 Initiated
Raymond James
Strong Buy
Aug-22-17 Upgrade
Jefferies
Hold → Buy
Jun-02-16 Initiated
Sterne Agee CRT
Neutral
Apr-15-16 Initiated
Sidoti
Buy
$9
Mar-17-09 Reiterated
Jefferies & Co
Buy
$12 → $4
Oct-15-08 Initiated
RBC Capital Mkts
Sector Perform
$4
Jul-14-08 Upgrade
Stanford Research
Hold → Buy
$9
Apr-02-08 Upgrade
Morgan Keegan
Mkt Perform → Outperform
Mar-14-08 Downgrade
Morgan Keegan
Outperform → Mkt Perform
Dec-19-07 Initiated
Leerink Swann
Outperform
Dec-07-07 Initiated
Stanford Research
Hold
$10.40
Nov-07-07 Initiated
Morgan Keegan
Outperform
Oct-19-07 Initiated
Deutsche Securities
Buy
$11.50
Show Previous Ratings
Sep-05-24 06:00AM
Sep-03-24 06:00AM
Aug-22-24 11:42PM
Aug-12-24 08:46AM
Aug-07-24 10:30PM
08:05PM
Loading…
08:05PM
07:03PM
(Associated Press Finance)
04:10PM
Aug-01-24 10:01AM
Jul-29-24 08:25AM
Jul-20-24 09:51AM
Jul-16-24 06:00AM
Jun-20-24 07:00PM
06:00AM
Jun-19-24 02:39AM
03:14AM
Loading…
Jun-15-24 03:14AM
Jun-14-24 03:05AM
Jun-13-24 02:45AM
02:45AM
Jun-11-24 07:01PM
07:01PM
10:50AM
06:00AM
Jun-07-24 06:00AM
Jun-06-24 09:15AM
Jun-05-24 12:45PM
Jun-04-24 12:00PM
Jun-03-24 06:00AM
May-15-24 06:14AM
May-13-24 06:00AM
06:29PM
Loading…
May-10-24 06:29PM
May-09-24 04:02AM
May-08-24 09:57PM
06:30PM
05:38PM
(Associated Press Finance)
04:05PM
May-07-24 07:50AM
May-01-24 10:01AM
Apr-30-24 12:10PM
Apr-29-24 08:00AM
Apr-22-24 06:00AM
Apr-18-24 04:05PM
09:18AM
Apr-12-24 06:00AM
Apr-11-24 06:00AM
Apr-10-24 11:41AM
06:00AM
Apr-03-24 06:00AM
Apr-02-24 06:00AM
Mar-12-24 04:05PM
Mar-07-24 09:54PM
04:05PM
Mar-05-24 10:22AM
06:00AM
Mar-04-24 12:00PM
12:00PM
06:00AM
Mar-02-24 01:49AM
(Thomson Reuters StreetEvents)
Mar-01-24 08:37PM
08:37PM
Feb-29-24 05:17PM
(Associated Press Finance)
04:10PM
Feb-27-24 04:05PM
Feb-15-24 06:00AM
Feb-13-24 06:00AM
Jan-24-24 06:00AM
Jan-08-24 06:00AM
Dec-08-23 11:27AM
11:05AM
Dec-05-23 08:59PM
06:00AM
Nov-27-23 06:05AM
06:00AM
Nov-15-23 06:00AM
Nov-14-23 08:55AM
Nov-10-23 02:43PM
Nov-08-23 08:15PM
07:09PM
(Associated Press Finance)
04:30PM
Oct-27-23 09:40AM
Oct-17-23 06:00AM
Sep-28-23 07:43AM
Sep-20-23 09:42AM
Sep-19-23 09:00AM
Sep-05-23 07:54AM
Sep-01-23 11:19AM
Aug-17-23 10:21AM
Aug-08-23 07:15AM
06:12AM
06:00AM
Jul-31-23 06:00AM
Jul-26-23 04:24PM
(The Wall Street Journal)
Jul-21-23 06:00AM
Jun-21-23 08:00PM
Jun-16-23 04:01PM
Jun-15-23 08:46AM
Jun-13-23 11:36PM
04:01PM
Jun-05-23 06:00AM
May-24-23 06:31AM
RadNet, Inc. provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and reduce unnecessary invasive procedures. The firm offers magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures. RadNet was founded by Howard G. Berger in 1980 and is headquartered in Los Angeles, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Murdock Michael N EVP, Mergers and Acquisitions Aug 21 '24 Sale 62.78 15,000 941,702 48,144 Aug 22 05:12 PM Murdock Michael N Officer Aug 20 '24 Proposed Sale 62.50 15,000 937,500 Aug 20 03:28 PM Patel Mital EVP, Chief Admin Officer Jun 18 '24 Sale 59.00 29,800 1,758,200 202,146 Jun 20 05:00 PM Patel Mital EVP, Chief Admin Officer Jun 17 '24 Sale 60.00 10,200 612,000 231,946 Jun 20 05:00 PM SPURLOCK GREGORY E. Director Jun 18 '24 Sale 59.75 7,167 428,228 2,591 Jun 18 06:23 PM SPURLOCK GREGORY E. Director Jun 17 '24 Sale 59.75 7,167 428,228 9,758 Jun 18 06:23 PM Murdock Michael N EVP, Mergers and Acquisitions Jun 12 '24 Sale 62.51 10,000 625,100 63,144 Jun 14 05:00 PM Levitt Lawrence L Director Jun 14 '24 Sale 57.77 4,000 231,080 172,657 Jun 14 05:00 PM Forthuber Stephen M Pres & COO-Eastern Operations Jun 12 '24 Sale 62.33 40,000 2,493,200 523,561 Jun 13 05:30 PM Sorensen Alma Gregory EVP, Chief Science Officer Jun 12 '24 Sale 62.34 10,000 623,400 1,239,205 Jun 13 05:30 PM Sorensen Alma Gregory EVP, Chief Science Officer Jun 11 '24 Sale 61.24 5,000 306,200 1,249,205 Jun 13 05:30 PM SWARTZ DAVID L Director Jun 10 '24 Sale 60.43 20,934 1,265,042 200,542 Jun 12 05:36 PM SWARTZ DAVID L Director Jun 12 '24 Sale 62.42 4,066 253,800 196,476 Jun 12 05:36 PM STOLPER MARK EVP, Chief Financial Officer Jun 10 '24 Sale 61.27 25,000 1,531,750 80,398 Jun 12 05:36 PM Levitt Lawrence L Director Jun 10 '24 Sale 60.85 16,000 973,600 174,066 Jun 12 05:35 PM HAMES NORMAN R Pres and COO-West Operations Jun 11 '24 Sale 61.40 35,000 2,149,000 245,919 Jun 12 05:33 PM HAMES NORMAN R Pres and COO-West Operations Jun 12 '24 Sale 63.08 18,597 1,173,099 227,322 Jun 12 05:33 PM HAMES NORMAN R Pres and COO-West Operations Jun 10 '24 Sale 61.15 15,000 917,250 280,919 Jun 12 05:33 PM HAMES NORMAN R Pres and COO-West Operations Jun 10 '24 Sale 61.09 5,000 305,450 24,889 Jun 12 05:33 PM Katz David Jeffrey EVP and Chief Legal Officer Jun 07 '24 Sale 61.26 16,400 1,004,664 65,441 Jun 11 05:00 PM Gordon Christine Nayoma Director Jun 07 '24 Sale 61.30 3,000 183,900 12,379 Jun 11 05:00 PM Gordon Christine Nayoma Director Jun 10 '24 Sale 61.03 1,500 91,545 10,879 Jun 11 05:00 PM Murdock Michael N EVP & Chief Development Offcr Dec 05 '23 Sale 35.02 10,115 354,227 68,432 Dec 07 04:05 PM Gordon Christine Nayoma Director Nov 27 '23 Sale 32.40 3,000 97,200 10,385 Nov 28 04:02 PM
Index -
P/E -
EPS (ttm) -1.63
Insider Own 41.46%
Shs Outstand 50.48M
Perf Week -7.41%
Market Cap 285.68M
Forward P/E -
EPS next Y -1.24
Insider Trans 18.71%
Shs Float 31.14M
Perf Month 86.46%
Income -81.45M
PEG -
EPS next Q -0.35
Inst Own 48.63%
Short Float 6.36%
Perf Quarter 283.57%
Sales 80.03M
P/S 3.57
EPS this Y 45.48%
Inst Trans -2.99%
Short Ratio 1.46
Perf Half Y 219.64%
Book/sh 2.12
P/B 2.54
EPS next Y -1.36%
ROA -37.49%
Short Interest 1.98M
Perf Year 235.62%
Cash/sh 1.63
P/C 3.28
EPS next 5Y -13.70%
ROE -56.49%
52W Range 0.89 - 7.20
Perf YTD 155.71%
Dividend Est. -
P/FCF -
EPS past 5Y -28.46%
ROI -54.48%
52W High -25.42%
Beta 1.92
Dividend TTM -
Quick Ratio 3.05
Sales past 5Y 18.20%
Gross Margin 27.76%
52W Low 502.96%
ATR (14) 0.66
Dividend Ex-Date -
Current Ratio 3.18
EPS Y/Y TTM 30.89%
Oper. Margin -101.13%
RSI (14) 57.35
Volatility 13.49% 16.01%
Employees 225
Debt/Eq 0.42
Sales Y/Y TTM 19.20%
Profit Margin -101.78%
Recom 1.33
Target Price 7.05
Option/Short Yes / Yes
LT Debt/Eq 0.33
EPS Q/Q 51.38%
Payout -
Rel Volume 0.51
Prev Close 5.16
Sales Surprise 17.20%
EPS Surprise 35.71%
Sales Q/Q 35.22%
Earnings Aug 07 AMC
Avg Volume 1.36M
Price 5.37
SMA20 2.45%
SMA50 53.80%
SMA200 170.68%
Trades
Volume 695,207
Change 4.07%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-06-23 Upgrade
Needham
Hold → Buy
$8
Feb-06-23 Upgrade
Needham
Hold → Buy
Jan-07-22 Upgrade
BofA Securities
Neutral → Buy
$27 → $23
Nov-05-21 Downgrade
Morgan Stanley
Overweight → Equal-Weight
Nov-03-21 Downgrade
Needham
Buy → Hold
Oct-15-21 Resumed
Cowen
Outperform
Sep-20-21 Reiterated
Needham
Buy
$33 → $28
May-06-21 Upgrade
Oppenheimer
Perform → Outperform
$28
Jan-28-21 Initiated
Truist
Buy
$50
Jan-04-21 Downgrade
BofA Securities
Buy → Neutral
$40
Nov-12-20 Reiterated
Needham
Buy
$25 → $32
Nov-06-20 Downgrade
Oppenheimer
Outperform → Perform
Oct-19-20 Initiated
Citigroup
Buy
$35
Oct-08-20 Initiated
BTIG Research
Buy
$35
Aug-27-20 Initiated
H.C. Wainwright
Buy
$30
Aug-18-20 Initiated
Needham
Buy
$25
Sep-26-19 Upgrade
BofA/Merrill
Neutral → Buy
$22
Jul-15-19 Initiated
Oppenheimer
Outperform
$29
Jul-15-19 Initiated
Morgan Stanley
Overweight
$28
Jul-15-19 Initiated
Cowen
Outperform
Show Previous Ratings
Aug-22-24 04:01PM
Aug-21-24 06:13PM
Aug-19-24 04:05PM
Aug-16-24 08:30AM
Aug-13-24 09:15AM
05:30PM
Loading…
Aug-07-24 05:30PM
04:35PM
(Associated Press Finance)
04:01PM
Aug-06-24 04:05PM
Jul-31-24 04:01PM
Jul-24-24 04:01PM
Jul-11-24 09:00AM
Jun-18-24 04:01PM
Jun-13-24 08:00AM
Jun-04-24 04:05PM
(Business Wire) -6.90%
+8.89%
09:05AM
Loading…
May-31-24 09:05AM
May-22-24 09:05AM
May-17-24 04:05PM
May-09-24 12:31PM
07:11AM
(Thomson Reuters StreetEvents)
04:00AM
May-08-24 08:59PM
04:22PM
(Associated Press Finance)
04:01PM
Apr-24-24 04:01PM
Mar-28-24 04:01PM
09:00AM
Mar-26-24 09:00AM
Mar-19-24 04:43PM
Feb-29-24 09:44AM
05:00PM
Loading…
Feb-28-24 05:00PM
(Associated Press Finance)
04:01PM
Feb-14-24 04:01PM
Jan-31-24 04:01PM
Jan-30-24 09:00AM
Jan-17-24 04:15PM
(Business Wire) +6.06%
-7.43%
Jan-16-24 09:05AM
Jan-05-24 09:05AM
Dec-04-23 09:15AM
Nov-28-23 04:15PM
(Business Wire) -8.33%
-9.09%
Nov-16-23 04:05PM
(GlobeNewswire) -7.21%
+6.80%
03:03PM
Nov-08-23 01:45PM
Nov-07-23 04:50PM
(Associated Press Finance) -9.17%
04:01PM
Oct-26-23 08:15AM
Oct-24-23 04:01PM
(Business Wire) +15.04%
-8.41%
Oct-21-23 04:25AM
Oct-19-23 07:15AM
Oct-18-23 07:15AM
Aug-29-23 04:01PM
Aug-24-23 07:01PM
Aug-15-23 10:20AM
Aug-08-23 05:40PM
04:32PM
(Associated Press Finance)
04:01PM
Aug-01-23 04:01PM
Jul-25-23 04:01PM
Jul-13-23 06:51AM
Jun-26-23 05:00PM
Jun-13-23 07:01PM
Jun-08-23 10:49AM
May-30-23 08:00AM
May-16-23 08:00AM
May-07-23 03:07PM
May-05-23 12:03PM
May-04-23 01:03PM
(Thomson Reuters StreetEvents)
May-03-23 05:45PM
04:37PM
04:01PM
May-02-23 08:00AM
Apr-19-23 04:01PM
Apr-08-23 08:10AM
Apr-05-23 04:01PM
08:45AM
Mar-22-23 08:55AM
Mar-07-23 08:55AM
Mar-02-23 04:05PM
Feb-28-23 12:00PM
Feb-26-23 07:31AM
Feb-24-23 01:32PM
(Thomson Reuters StreetEvents) -7.23%
Feb-23-23 04:01PM
Feb-09-23 04:01PM
Feb-07-23 10:07AM
Feb-06-23 04:01PM
01:41PM
Feb-03-23 12:38PM
08:45AM
Jan-19-23 10:17AM
(American City Business Journals) -9.43%
04:31AM
Jan-05-23 05:21AM
Jan-04-23 04:01PM
Dec-16-22 04:05PM
(Business Wire) -6.52%
-8.84%
Dec-14-22 04:02PM
Nov-30-22 08:55AM
Nov-21-22 04:01PM
Nov-07-22 04:05PM
02:16PM
Nov-02-22 05:15PM
04:01PM
Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Tempus AI, Inc. 10% Owner Aug 16 '24 Buy 5.07 3,500,000 17,745,000 12,718,800 Aug 20 04:17 PM Chen Richard CHIEF MEDICAL OFFICER AND EVP Jul 30 '24 Sale 2.97 524 1,556 127,227 Aug 01 05:16 PM Tachibana Aaron CFO AND COO Jul 30 '24 Sale 2.97 742 2,204 175,270 Aug 01 05:13 PM Chen Richard CHIEF MEDICAL OFFICER AND EVP Jun 17 '24 Sale 1.29 5,055 6,521 127,751 Jun 20 04:55 PM Tachibana Aaron CFO AND COO Jun 17 '24 Sale 1.29 7,176 9,257 176,012 Jun 20 04:54 PM Moore Stephen Michael SVP and Chief Legal Officer Jun 17 '24 Sale 1.29 1,585 2,045 69,081 Jun 20 04:53 PM Chen Richard CHIEF MEDICAL OFFICER AND EVP May 17 '24 Sale 1.38 940 1,297 132,806 May 21 09:14 PM Tachibana Aaron CFO AND COO May 17 '24 Sale 1.38 1,333 1,840 183,188 May 21 09:13 PM Moore Stephen Michael SVP and Chief Legal Officer May 17 '24 Sale 1.38 1,731 2,389 70,666 May 21 09:11 PM Moore Stephen Michael SVP and Chief Legal Officer Apr 30 '24 Sale 1.37 4,523 6,197 72,397 May 02 05:52 PM MYERS WOODROW A JR Director Mar 01 '24 Buy 1.67 10,000 16,700 26,116 Mar 05 05:15 PM Chen Richard CHIEF MEDICAL OFFICER AND EVP Jan 29 '24 Sale 1.37 526 721 128,870 Jan 31 04:30 PM Tachibana Aaron CFO AND COO Jan 29 '24 Sale 1.37 716 981 184,521 Jan 31 04:27 PM Chen Richard Chief Medical Officer and EVP Dec 15 '23 Sale 1.47 4,708 6,921 129,396 Dec 19 06:09 PM Tachibana Aaron CFO and COO Dec 15 '23 Sale 1.47 6,747 9,918 185,237 Dec 19 06:07 PM Moore Stephen Michael General Counsel Dec 15 '23 Sale 1.47 1,476 2,170 76,920 Dec 19 06:02 PM Moore Stephen Michael General Counsel Nov 16 '23 Sale 1.04 1,722 1,791 78,396 Nov 20 04:30 PM Tachibana Aaron CFO and COO Nov 16 '23 Sale 1.04 1,344 1,398 191,984 Nov 20 04:30 PM Chen Richard Chief Medical Officer and EVP Nov 16 '23 Sale 1.04 940 978 124,104 Nov 20 04:30 PM Hall Christopher M President and CEO Nov 01 '23 Sale 0.93 20,459 19,027 204,541 Nov 03 09:00 PM
Index -
P/E -
EPS (ttm) -2.97
Insider Own 0.36%
Shs Outstand 89.60M
Perf Week -13.22%
Market Cap 1.80B
Forward P/E 14.67
EPS next Y 1.37
Insider Trans 3.86%
Shs Float 89.28M
Perf Month -18.23%
Income -265.30M
PEG -
EPS next Q 0.25
Inst Own 116.27%
Short Float 7.47%
Perf Quarter -27.24%
Sales 2.88B
P/S 0.63
EPS this Y -59.78%
Inst Trans -
Short Ratio 4.72
Perf Half Y -45.23%
Book/sh 16.33
P/B 1.23
EPS next Y 143.16%
ROA -5.76%
Short Interest 6.67M
Perf Year -22.70%
Cash/sh 1.41
P/C 14.26
EPS next 5Y -8.80%
ROE -14.21%
52W Range 18.07 - 41.02
Perf YTD -42.44%
Dividend Est. -
P/FCF 7.95
EPS past 5Y -
ROI -10.01%
52W High -51.02%
Beta 0.65
Dividend TTM -
Quick Ratio 1.19
Sales past 5Y 6.72%
Gross Margin 13.98%
52W Low 11.18%
ATR (14) 1.24
Dividend Ex-Date -
Current Ratio 1.19
EPS Y/Y TTM -
Oper. Margin -1.81%
RSI (14) 33.68
Volatility 5.72% 6.54%
Employees 18000
Debt/Eq 0.82
Sales Y/Y TTM -
Profit Margin -9.22%
Recom 2.46
Target Price 24.10
Option/Short Yes / Yes
LT Debt/Eq 0.81
EPS Q/Q -504.33%
Payout -
Rel Volume 0.73
Prev Close 20.80
Sales Surprise -3.87%
EPS Surprise -144.44%
Sales Q/Q -16.47%
Earnings Aug 12 BMO
Avg Volume 1.41M
Price 20.09
SMA20 -10.46%
SMA50 -17.07%
SMA200 -34.73%
Trades
Volume 1,030,319
Change -3.41%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-08-24 Downgrade
Evercore ISI
Outperform → In-line
$31 → $27
Jul-24-24 Resumed
Barclays
Equal Weight
$30
Jun-06-24 Initiated
Goldman
Neutral
$28
May-29-24 Initiated
TD Cowen
Hold
$27
May-28-24 Initiated
Mizuho
Neutral
$27
Mar-22-24 Initiated
Robert W. Baird
Neutral
$43
Mar-06-24 Initiated
Deutsche Bank
Hold
$36
Jan-05-24 Initiated
William Blair
Mkt Perform
Jan-04-24 Initiated
Jefferies
Buy
$44
Dec-11-23 Upgrade
Citigroup
Neutral → Buy
$34 → $40
Dec-01-23 Upgrade
Evercore ISI
In-line → Outperform
$32 → $36
Nov-14-23 Upgrade
Barclays
Equal Weight → Overweight
$29 → $38
Oct-19-23 Initiated
Citigroup
Neutral
$32
Sep-14-23 Initiated
Evercore ISI
In-line
$31
Aug-16-23 Initiated
Barclays
Equal Weight
$29
Aug-07-23 Initiated
BofA Securities
Underperform
$27
Show Previous Ratings
Aug-13-24 12:58PM
(Morningstar Research) +10.88%
Aug-12-24 07:04PM
(Morningstar Research) -20.35%
07:00AM
Jul-17-24 07:00AM
Jul-11-24 08:42AM
08:00AM
Loading…
08:00AM
Jun-27-24 07:00AM
Jun-19-24 05:02PM
Jun-04-24 07:00AM
Jun-03-24 07:00AM
May-30-24 07:01PM
07:00AM
May-21-24 09:48AM
May-17-24 10:15PM
May-16-24 04:05PM
03:56PM
Loading…
May-15-24 03:56PM
May-14-24 06:43PM
03:01AM
May-13-24 06:50PM
(Morningstar Research) -14.90%
10:52AM
06:30AM
May-06-24 08:22AM
Apr-30-24 01:58PM
Apr-11-24 07:00AM
Mar-12-24 11:24AM
Mar-11-24 06:30AM
06:30AM
Feb-20-24 04:05PM
07:00AM
Jan-29-24 07:00AM
04:22PM
Loading…
Jan-09-24 04:22PM
Jan-08-24 07:00AM
Jan-05-24 04:53AM
Jan-04-24 08:00AM
Jan-02-24 07:00AM
Dec-13-23 07:00AM
Nov-20-23 07:00AM
Nov-14-23 08:33PM
(Morningstar Research) +5.05%
Nov-13-23 11:07AM
06:30AM
Nov-02-23 07:00AM
Oct-18-23 05:40AM
Oct-17-23 01:35PM
09:05AM
Oct-16-23 08:30PM
(The Wall Street Journal)
Oct-13-23 07:00AM
Oct-11-23 07:00AM
Oct-10-23 07:00AM
Oct-06-23 04:52AM
Sep-15-23 08:45PM
Sep-06-23 11:00AM
11:00AM
Aug-16-23 10:00AM
Aug-15-23 07:03AM
07:03AM
Aug-14-23 07:00AM
Aug-07-23 09:57AM
09:57AM
Jul-20-23 07:00AM
Jul-18-23 07:40AM
Jul-07-23 12:00PM
(The Wall Street Journal) -5.21%
Jun-28-23 06:08PM
Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. It operates under the Clinical Services and Enabling Services Segments. The Clinical Services segment provides services across the clinical pharmacology, clinical development, and other clinical service spectrum utilizing enabling services and technology through multiple delivery models. The Enabling Services segment provides technology solutions directly to customers that streamline complex randomization and optimize the trial drug supply process, while minimizing operational costs and supporting timely and accurate patient dosing. The company was founded on January 31, 2023 and is headquartered in Durham, NC.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Morais Mark A. Chief Operating Officer Aug 19 '24 Option Exercise 0.00 11,312 0 36,464 Aug 20 05:37 PM Mcconnell Jill G. Chief Financial Officer Aug 19 '24 Option Exercise 0.00 11,312 0 38,194 Aug 20 05:36 PM Pike Thomas Chief Executive Officer Aug 19 '24 Option Exercise 0.00 125,691 0 183,518 Aug 20 05:34 PM Smith David Ross Director Jul 18 '24 Option Exercise 0.00 6,354 0 6,354 Jul 19 05:24 PM NEUPERT PETER M Director Jul 18 '24 Option Exercise 0.00 6,354 0 28,350 Jul 19 05:23 PM Pesicka Edward A Director Jul 18 '24 Option Exercise 0.00 6,354 0 6,354 Jul 19 05:23 PM ECKERT R ANDREW Director Jul 18 '24 Option Exercise 0.00 6,354 0 6,354 Jul 19 05:22 PM Ray Amrit Director Jul 18 '24 Option Exercise 0.00 6,354 0 6,354 Jul 19 05:21 PM Hanson James S. General Counsel Jun 12 '24 Buy 25.30 2,000 50,600 7,475 Jun 12 06:28 PM Hanson James S. General Counsel Jun 03 '24 Option Exercise 0.00 7,706 0 7,706 Jun 03 07:08 PM Warren Amanda M. Chief Accounting Officer Jun 03 '24 Option Exercise 0.00 3,842 0 6,411 Jun 03 07:05 PM Mcconnell Jill G. Chief Financial Officer Jun 03 '24 Option Exercise 0.00 11,000 0 31,717 Jun 03 07:03 PM Morais Mark A. Chief Operating Officer Jun 03 '24 Option Exercise 0.00 11,000 0 29,406 Jun 03 07:01 PM Pike Thomas Chief Executive Officer May 29 '24 Buy 24.81 10,000 248,066 57,827 May 30 04:34 PM Larson Betty D Former Director Mar 30 '24 Option Exercise 0.00 6,354 0 6,354 Apr 01 06:33 AM Mcconnell Jill G. Chief Financial Officer Mar 04 '24 Option Exercise 0.00 20,776 0 26,815 Mar 06 06:42 PM Morais Mark A. Chief Operating Officer Mar 04 '24 Option Exercise 0.00 15,368 0 22,856 Mar 06 06:40 PM Mcconnell Jill G. Chief Financial Officer Feb 11 '24 Option Exercise 0.00 1,544 0 6,486 Feb 13 05:05 PM Warren Amanda M. Chief Accounting Officer Feb 11 '24 Option Exercise 0.00 1,068 0 2,935 Feb 13 05:03 PM Morais Mark A. Chief Operating Officer Feb 11 '24 Option Exercise 0.00 1,210 0 7,839 Feb 13 05:01 PM Mcconnell Jill G. Chief Financial Officer Feb 07 '24 Option Exercise 0.00 1,680 0 5,437 Feb 08 07:00 PM Warren Amanda M. Chief Accounting Officer Feb 07 '24 Option Exercise 0.00 1,182 0 2,272 Feb 08 06:58 PM Morais Mark A. Chief Operating Officer Feb 07 '24 Option Exercise 0.00 2,249 0 7,280 Feb 08 06:55 PM Mcconnell Jill G. Chief Financial Officer Feb 02 '24 Option Exercise 0.00 1,708 0 4,262 Feb 05 05:19 PM Warren Amanda M. Chief Accounting Officer Feb 02 '24 Option Exercise 0.00 1,046 0 1,449 Feb 05 05:17 PM Morais Mark A. Chief Operating Officer Feb 02 '24 Option Exercise 0.00 1,787 0 5,183 Feb 05 05:17 PM Pike Thomas Chief Executive Officer Jan 09 '24 Option Exercise 0.00 40,220 0 60,220 Jan 11 06:12 PM Morais Mark A. Chief Operating Officer Dec 15 '23 Option Exercise 0.00 406 0 3,891 Dec 15 05:41 PM
Index RUT
P/E -
EPS (ttm) -0.99
Insider Own 41.80%
Shs Outstand 30.74M
Perf Week 3.72%
Market Cap 241.93M
Forward P/E -
EPS next Y -0.94
Insider Trans -2.06%
Shs Float 19.42M
Perf Month -2.03%
Income -31.54M
PEG -
EPS next Q -0.23
Inst Own 44.74%
Short Float 4.05%
Perf Quarter -14.00%
Sales 0.11M
P/S 2199.39
EPS this Y 16.81%
Inst Trans 0.25%
Short Ratio 4.11
Perf Half Y -19.71%
Book/sh 1.79
P/B 4.05
EPS next Y 2.07%
ROA -34.74%
Short Interest 0.79M
Perf Year 331.55%
Cash/sh 1.53
P/C 4.75
EPS next 5Y -
ROE -44.77%
52W Range 1.52 - 12.35
Perf YTD 21.24%
Dividend Est. -
P/FCF -
EPS past 5Y -21.21%
ROI -52.47%
52W High -41.32%
Beta 1.05
Dividend TTM -
Quick Ratio 2.08
Sales past 5Y 109.61%
Gross Margin -1029.91%
52W Low 376.97%
ATR (14) 0.48
Dividend Ex-Date -
Current Ratio 2.08
EPS Y/Y TTM 26.38%
Oper. Margin -32957.94%
RSI (14) 49.79
Volatility 6.90% 5.90%
Employees 57
Debt/Eq 0.02
Sales Y/Y TTM -71.47%
Profit Margin -29471.96%
Recom 1.67
Target Price 2.75
Option/Short Yes / Yes
LT Debt/Eq 0.01
EPS Q/Q 25.68%
Payout -
Rel Volume 0.26
Prev Close 7.22
Sales Surprise -76.56%
EPS Surprise 5.27%
Sales Q/Q -80.49%
Earnings Aug 07 AMC
Avg Volume 191.62K
Price 7.25
SMA20 1.09%
SMA50 2.62%
SMA200 -3.43%
Trades
Volume 49,759
Change 0.42%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-30-22 Downgrade
Citigroup
Buy → Neutral
$18 → $4
Nov-19-21 Initiated
Oppenheimer
Outperform
$19
Oct-15-21 Resumed
Cowen
Outperform
Sep-04-24 04:53PM
Aug-08-24 08:30AM
Aug-07-24 05:50PM
04:05PM
Jul-25-24 08:30AM
08:30AM
Loading…
Jul-09-24 08:30AM
Jul-01-24 08:30AM
Jun-16-24 06:17AM
May-28-24 08:30AM
May-10-24 03:10PM
May-09-24 10:44AM
May-08-24 08:57PM
04:05PM
Apr-29-24 02:15PM
Mar-29-24 01:32AM
01:27AM
Loading…
Mar-27-24 01:27AM
Mar-25-24 12:00PM
Mar-21-24 09:57AM
Mar-20-24 08:54PM
05:33PM
05:20PM
04:05PM
Mar-12-24 11:40AM
Mar-04-24 08:30AM
Feb-29-24 11:14AM
Dec-11-23 12:00PM
Dec-06-23 01:19PM
08:30AM
Nov-22-23 01:00PM
Nov-12-23 10:59AM
06:29PM
Loading…
Nov-08-23 06:29PM
04:05PM
Oct-25-23 08:30AM
Sep-21-23 08:30AM
Aug-31-23 09:35AM
Aug-30-23 09:35AM
Aug-09-23 05:50PM
04:05PM
Jul-31-23 08:30AM
May-25-23 04:15PM
May-15-23 05:15PM
May-10-23 06:05PM
04:05PM
May-04-23 07:31AM
Apr-27-23 08:30AM
Apr-24-23 09:35AM
Mar-27-23 12:00PM
02:27AM
Mar-24-23 06:29AM
Mar-22-23 05:35PM
04:05PM
Mar-09-23 04:05PM
Feb-23-23 04:20PM
Feb-18-23 07:43AM
Feb-15-23 08:30AM
Nov-29-22 08:30AM
Nov-15-22 08:30AM
Nov-09-22 06:15PM
04:05PM
Nov-04-22 04:00PM
Oct-04-22 08:30AM
Sep-22-22 08:30AM
Sep-20-22 07:19AM
Aug-11-22 07:00AM
Aug-10-22 05:55PM
04:05PM
Aug-03-22 10:00AM
Jul-28-22 08:30AM
Jun-06-22 02:15PM
May-19-22 04:15PM
May-18-22 03:03PM
May-10-22 04:05PM
May-05-22 08:30AM
May-02-22 08:30AM
Apr-12-22 08:30AM
Mar-30-22 07:30AM
Mar-29-22 04:00PM
Mar-18-22 12:00PM
07:00AM
Mar-03-22 08:30AM
Feb-17-22 08:30AM
Feb-07-22 08:30AM
Feb-01-22 08:30AM
Dec-15-21 08:30AM
Dec-02-21 08:00AM
Dec-01-21 11:40AM
Nov-30-21 08:00AM
Nov-10-21 09:01AM
Nov-09-21 04:01PM
Nov-08-21 04:20PM
Nov-04-21 08:00AM
Nov-03-21 08:00AM
Nov-02-21 08:00AM
Oct-27-21 08:30AM
Oct-15-21 10:59AM
Sep-28-21 08:30AM
Sep-20-21 08:30AM
Sep-15-21 08:00AM
Sep-14-21 08:00AM
Sep-13-21 08:00AM
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. It focuses on developing blood tests to predict the risks of preterm birth, preeclampsia and other pregnancy complications. The company was founded by Steven W. Graves, Dennis Farrar and M. Sean Esplin in 2008 and is headquartered in Salt Lake City, UT.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Lindgardt Zhenya Officer Aug 07 '24 Proposed Sale 7.42 12,327 91,405 Aug 08 05:07 PM Harrison Robert Gardner Officer Aug 07 '24 Proposed Sale 7.41 5,022 37,238 Aug 08 05:05 PM Kearney Paul Officer Aug 07 '24 Proposed Sale 7.41 4,333 32,129 Aug 08 05:04 PM Mirza Mansoor Raza Director Aug 07 '24 Proposed Sale 7.42 101 749 Aug 08 05:02 PM Boniface John J. Officer Aug 07 '24 Proposed Sale 7.41 5,022 37,238 Aug 08 05:01 PM Jackson Benjamin Officer Aug 07 '24 Proposed Sale 7.41 5,022 37,238 Aug 08 05:00 PM Aerts Austin Officer Aug 07 '24 Proposed Sale 7.41 6,760 50,125 Aug 08 04:58 PM Boniface John J. Chief Scientific Officer Aug 07 '24 Sale 7.42 5,022 37,263 129,847 Aug 08 04:51 PM Harrison Robert Gardner Chief Information Officer Aug 07 '24 Sale 7.42 5,022 37,263 135,773 Aug 08 04:50 PM Kearney Paul Chief Data Officer Aug 07 '24 Sale 7.42 4,333 32,151 180,967 Aug 08 04:50 PM Lindgardt Zhenya Chief Executive Officer Aug 07 '24 Sale 7.42 12,327 91,466 856,918 Aug 08 04:50 PM Mirza Mansoor Raza Director Aug 07 '24 Sale 7.42 101 749 7,016 Aug 08 04:50 PM Jackson Benjamin General Counsel Aug 07 '24 Sale 7.42 5,022 37,263 140,255 Aug 08 04:50 PM Aerts Austin Chief Financial Officer Aug 07 '24 Sale 7.42 6,760 50,159 303,721 Aug 08 04:49 PM Lindgardt Zhenya Chief Executive Officer Jun 10 '24 Sale 8.11 26,867 217,891 869,245 Jun 11 04:50 PM Aerts Austin Chief Financial Officer Jun 10 '24 Sale 8.11 5,415 43,916 310,481 Jun 11 04:50 PM Kearney Paul Chief Data Officer May 15 '24 Sale 8.24 10,387 85,589 185,300 May 15 06:23 PM Kearney Paul Chief Data Officer May 08 '24 Sale 9.59 4,205 40,326 154,833 May 10 05:42 PM Boniface John J. Chief Scientific Officer May 08 '24 Sale 9.59 4,902 47,010 134,869 May 10 05:41 PM Jackson Benjamin General Counsel May 08 '24 Sale 9.59 4,902 47,010 145,277 May 10 05:41 PM Aerts Austin Chief Financial Officer May 08 '24 Sale 9.59 6,592 63,217 315,896 May 10 05:41 PM Lindgardt Zhenya Chief Executive Officer May 08 '24 Sale 9.59 11,992 115,003 896,112 May 10 05:41 PM Harrison Robert Gardner Chief Information Officer May 08 '24 Sale 9.59 4,902 47,010 140,795 May 10 05:40 PM Boniface John J. Chief Scientific Officer Mar 27 '24 Option Exercise 0.91 48,909 44,507 188,680 Mar 28 05:56 PM Boniface John J. Chief Scientific Officer Mar 28 '24 Option Exercise 0.91 24,474 22,271 164,245 Mar 28 05:56 PM Boniface John J. Chief Scientific Officer Mar 27 '24 Sale 9.62 52,662 506,608 139,771 Mar 28 05:56 PM Boniface John J. Chief Scientific Officer Mar 28 '24 Sale 9.04 24,474 221,245 139,771 Mar 28 05:56 PM Lindgardt Zhenya Chief Executive Officer Mar 26 '24 Sale 9.37 38,899 364,484 908,104 Mar 26 08:00 PM Aerts Austin Chief Financial Officer Mar 26 '24 Sale 9.37 8,092 75,822 322,488 Mar 26 08:00 PM Boniface John J. Chief Scientific Officer Mar 26 '24 Sale 9.55 21,438 204,733 143,524 Mar 26 05:38 PM Boniface John J. Chief Scientific Officer Mar 25 '24 Sale 9.10 22,163 201,683 164,962 Mar 26 04:20 PM Boniface John J. Chief Scientific Officer Mar 06 '24 Sale 9.02 1,664 15,009 187,125 Mar 07 04:16 PM Aerts Austin Chief Financial Officer Mar 06 '24 Sale 9.02 444 4,005 330,580 Mar 07 04:16 PM Kearney Paul Chief Data Officer Mar 06 '24 Sale 9.02 1,028 9,273 159,038 Mar 07 04:16 PM Harrison Robert Gardner Chief Information Officer Mar 06 '24 Sale 9.02 2,138 19,285 145,697 Mar 07 04:15 PM Jackson Benjamin General Counsel Mar 06 '24 Sale 9.02 1,856 16,741 150,179 Mar 07 04:15 PM Jackson Benjamin General Counsel Feb 06 '24 Sale 8.03 5,665 45,490 152,035 Feb 07 04:57 PM Boniface John J. Chief Scientific Officer Feb 06 '24 Sale 8.03 5,665 45,490 188,789 Feb 07 04:57 PM Kearney Paul Chief Data Officer Feb 06 '24 Sale 8.03 4,984 40,022 160,066 Feb 07 04:56 PM Harrison Robert Gardner Chief Information Officer Feb 06 '24 Sale 8.03 5,665 45,490 147,835 Feb 07 04:56 PM Lindgardt Zhenya Chief Executive Officer Feb 06 '24 Sale 8.03 27,997 224,816 947,003 Feb 07 04:56 PM Aerts Austin Chief Financial Officer Feb 06 '24 Sale 8.03 9,786 78,582 331,024 Feb 07 04:56 PM Jackson Benjamin General Counsel Dec 07 '23 Sale 5.22 10,000 52,200 157,700 Dec 07 09:35 PM Boniface John J. Chief Scientific Officer Dec 07 '23 Sale 4.80 5,000 24,000 194,454 Dec 07 09:35 PM
Index RUT
P/E -
EPS (ttm) -4.09
Insider Own 4.99%
Shs Outstand 121.63M
Perf Week -8.48%
Market Cap 2.92B
Forward P/E -
EPS next Y -2.85
Insider Trans 0.03%
Shs Float 116.88M
Perf Month -30.12%
Income -490.76M
PEG -
EPS next Q -0.75
Inst Own 95.30%
Short Float 8.03%
Perf Quarter -18.23%
Sales 643.81M
P/S 4.53
EPS this Y 23.73%
Inst Trans 1.88%
Short Ratio 4.59
Perf Half Y 28.55%
Book/sh -0.01
P/B -
EPS next Y 12.83%
ROA -28.46%
Short Interest 9.39M
Perf Year -32.80%
Cash/sh 8.42
P/C 2.82
EPS next 5Y 29.20%
ROE -337.16%
52W Range 15.81 - 37.04
Perf YTD -12.27%
Dividend Est. -
P/FCF -
EPS past 5Y -8.88%
ROI -37.41%
52W High -35.93%
Beta 1.11
Dividend TTM -
Quick Ratio 6.07
Sales past 5Y 49.27%
Gross Margin 59.87%
52W Low 50.09%
ATR (14) 1.45
Dividend Ex-Date -
Current Ratio 6.40
EPS Y/Y TTM 16.79%
Oper. Margin -79.30%
RSI (14) 31.06
Volatility 3.99% 4.87%
Employees 1779
Debt/Eq -
Sales Y/Y TTM 26.20%
Profit Margin -76.23%
Recom 1.38
Target Price 41.50
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q -25.31%
Payout -
Rel Volume 1.29
Prev Close 24.33
Sales Surprise 9.01%
EPS Surprise -11.48%
Sales Q/Q 29.23%
Earnings Aug 07 AMC
Avg Volume 2.05M
Price 23.73
SMA20 -13.72%
SMA50 -20.11%
SMA200 -3.80%
Trades
Volume 2,645,831
Change -2.47%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-28-24 Upgrade
Guggenheim
Neutral → Buy
$36
Jun-03-24 Resumed
Jefferies
Buy
$32
Apr-24-24 Resumed
Craig Hallum
Buy
$28
Dec-14-23 Initiated
Guggenheim
Neutral
Dec-13-23 Initiated
Wolfe Research
Peer Perform
Nov-13-23 Upgrade
Raymond James
Mkt Perform → Outperform
$27
Sep-28-23 Initiated
Bernstein
Outperform
$34
Sep-27-23 Upgrade
Piper Sandler
Neutral → Overweight
$40
Jul-05-23 Resumed
JP Morgan
Overweight
$65
May-26-23 Upgrade
Citigroup
Neutral → Buy
$28 → $40
May-05-23 Initiated
UBS
Buy
$40
Mar-09-23 Downgrade
Citigroup
Buy → Neutral
$60 → $33
Jan-05-23 Initiated
Scotiabank
Sector Outperform
$36
Nov-01-22 Downgrade
Piper Sandler
Overweight → Neutral
$65 → $50
Oct-19-22 Initiated
Craig Hallum
Buy
$88
Oct-06-22 Initiated
Stephens
Overweight
$99
Aug-25-22 Initiated
Credit Suisse
Outperform
$80
Jun-03-22 Initiated
Piper Sandler
Overweight
$65
Apr-28-22 Resumed
BTIG Research
Buy
$135 → $115
Feb-24-22 Reiterated
Wells Fargo
Overweight
$150 → $115
Show Previous Ratings
Aug-27-24 04:05PM
Aug-26-24 12:56PM
10:40AM
Aug-23-24 10:45AM
06:00AM
05:00PM
Loading…
Aug-22-24 05:00PM
Aug-12-24 11:45AM
Aug-09-24 04:48PM
Aug-08-24 04:05PM
09:35AM
Aug-07-24 07:30PM
06:50PM
05:49PM
(Associated Press Finance)
04:05PM
08:05AM
09:15AM
Loading…
Aug-06-24 09:15AM
Aug-01-24 04:02PM
(Investor's Business Daily) -5.04%
08:30AM
08:00AM
Jul-31-24 09:45AM
Jul-30-24 06:32AM
05:17AM
Jul-29-24 04:06PM
(Yahoo Finance Video) +6.91%
02:16PM
07:58AM
06:30AM
Jul-24-24 04:05PM
Jul-23-24 08:05AM
01:38AM
Jul-21-24 06:00AM
05:00PM
Loading…
Jul-18-24 05:00PM
Jul-05-24 03:01PM
Jul-03-24 11:11AM
07:00AM
Jul-02-24 06:15AM
Jun-27-24 03:28PM
Jun-26-24 09:35AM
Jun-25-24 09:55AM
Jun-04-24 08:05AM
Jun-03-24 09:18AM
May-31-24 08:05AM
May-30-24 08:05AM
May-27-24 11:34AM
09:30AM
May-24-24 04:06PM
(Investor's Business Daily) +13.37%
01:16PM
01:15PM
10:28AM
(The Wall Street Journal)
09:03AM
(Investor's Business Daily)
08:37AM
May-23-24 07:03PM
10:52AM
07:05AM
May-22-24 04:05PM
08:15AM
May-21-24 04:36PM
09:53AM
08:05AM
May-17-24 08:05AM
May-16-24 08:05AM
May-15-24 06:45PM
May-13-24 10:03AM
May-10-24 06:16PM
(Morningstar Research) +15.07%
01:58PM
01:09PM
May-09-24 06:30PM
06:05PM
04:58PM
(Associated Press Finance)
04:05PM
May-07-24 04:05PM
11:29AM
08:00AM
May-06-24 09:15AM
Apr-29-24 04:01PM
11:18AM
Apr-22-24 08:52AM
Apr-18-24 04:05PM
Apr-03-24 08:05AM
Apr-02-24 04:02PM
(Investor's Business Daily)
Apr-01-24 08:35AM
Mar-30-24 07:43PM
Mar-13-24 05:09PM
(Associated Press Finance)
05:00PM
Mar-06-24 04:30PM
Mar-01-24 05:30AM
Feb-28-24 06:46PM
Feb-26-24 02:13AM
Feb-23-24 11:48AM
Feb-22-24 07:00PM
06:20PM
05:23PM
(Associated Press Finance)
04:38PM
04:05PM
09:55AM
Feb-16-24 03:10AM
Feb-15-24 04:05PM
10:00AM
Feb-07-24 09:00AM
Feb-02-24 09:35AM
Feb-01-24 04:05PM
Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2011 and is headquartered in Palo Alto, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Joyce Meghan V. Director Sep 04 '24 Option Exercise 0.00 67 0 10,412 Sep 05 04:52 PM Saia John G. Chief Legal Officer Sep 01 '24 Option Exercise 0.00 263 0 29,306 Sep 03 04:47 PM Kalia Kumud Chief Information Officer Sep 01 '24 Option Exercise 0.00 710 0 18,666 Sep 03 04:46 PM Chudova Darya Chief Technology Officer Sep 01 '24 Option Exercise 0.00 316 0 44,379 Sep 03 04:45 PM Krognes Steve E. Director Aug 31 '24 Option Exercise 0.00 155 0 9,603 Sep 03 04:43 PM Tariq Musa Director Aug 15 '24 Option Exercise 0.00 250 0 4,247 Aug 19 05:18 PM POTTER MYRTLE S Director Aug 15 '24 Option Exercise 0.00 68 0 13,448 Aug 19 05:17 PM Joyce Meghan V. Director Aug 04 '24 Option Exercise 0.00 66 0 10,345 Aug 05 06:10 PM Krognes Steve E. Director Jul 31 '24 Option Exercise 0.00 154 0 9,448 Aug 01 06:46 PM Tariq Musa Director Jul 15 '24 Option Exercise 0.00 250 0 3,997 Jul 16 04:35 PM POTTER MYRTLE S Director Jul 15 '24 Option Exercise 0.00 69 0 13,380 Jul 16 04:33 PM Joyce Meghan V. Director Jul 04 '24 Option Exercise 0.00 66 0 10,279 Jul 08 05:29 PM Saia John G. Chief Legal Officer Jul 01 '24 Option Exercise 0.00 974 0 29,391 Jul 02 04:58 PM Kalia Kumud Chief Information Officer Jul 01 '24 Option Exercise 0.00 1,607 0 18,530 Jul 02 04:57 PM Freeman Chris Chief Commercial Officer Jul 01 '24 Option Exercise 0.00 1,928 0 26,527 Jul 02 04:55 PM EAGLE CRAIG Chief Medical Officer Jul 01 '24 Option Exercise 0.00 1,714 0 19,108 Jul 02 04:54 PM Chudova Darya Chief Technology Officer Jul 01 '24 Option Exercise 0.00 1,339 0 44,541 Jul 02 04:53 PM Talasaz AmirAli Co-Chief Executive Officer Jun 30 '24 Option Exercise 0.00 11,462 0 2,204,589 Jul 02 04:51 PM Krognes Steve E. Director Jun 30 '24 Option Exercise 0.00 154 0 9,294 Jul 02 04:49 PM Eltoukhy Helmy Co-Chief Executive Officer Jun 30 '24 Option Exercise 0.00 11,462 0 2,304,423 Jul 02 04:47 PM Tariq Musa Director Jun 15 '24 Option Exercise 0.00 250 0 3,747 Jun 17 06:44 PM Saia John G. Chief Legal Officer Jun 15 '24 Option Exercise 0.00 4,017 0 29,851 Jun 17 06:43 PM POTTER MYRTLE S Director Jun 15 '24 Option Exercise 0.00 68 0 13,311 Jun 17 06:42 PM Kalia Kumud Chief Information Officer Jun 15 '24 Option Exercise 0.00 2,510 0 17,819 Jun 17 06:41 PM Freeman Chris Chief Commercial Officer Jun 15 '24 Option Exercise 0.00 10,402 0 27,469 Jun 17 06:40 PM EAGLE CRAIG Chief Medical Officer Jun 15 '24 Option Exercise 0.00 5,523 0 19,365 Jun 17 06:38 PM Bell Michael Brian Chief Financial Officer Jun 15 '24 Option Exercise 0.00 9,267 0 21,720 Jun 17 06:37 PM POTTER MYRTLE S Director Jun 12 '24 Option Exercise 0.00 5,592 0 13,243 Jun 13 08:58 PM Krognes Steve E. Director Jun 12 '24 Option Exercise 0.00 5,592 0 9,140 Jun 13 08:56 PM Joyce Meghan V. Director Jun 12 '24 Option Exercise 0.00 5,592 0 10,213 Jun 13 08:54 PM Gadde Vijaya Director Jun 12 '24 Option Exercise 0.00 5,592 0 17,640 Jun 13 08:53 PM CLARK IAN T Director Jun 12 '24 Option Exercise 0.00 6,776 0 15,677 Jun 13 08:51 PM Joyce Meghan V. Director Jun 04 '24 Option Exercise 0.00 67 0 4,721 Jun 05 04:56 PM Joyce Meghan V. Director Jun 04 '24 Sale 27.87 100 2,787 4,621 Jun 05 04:56 PM Saia John G. Chief Legal Officer Jun 01 '24 Option Exercise 0.00 263 0 25,928 Jun 03 06:25 PM Kalia Kumud Chief Information Officer Jun 01 '24 Option Exercise 0.00 711 0 15,563 Jun 03 06:23 PM Chudova Darya Chief Technology Officer Jun 01 '24 Option Exercise 0.00 315 0 43,315 Jun 03 06:21 PM Krognes Steve E. Director May 31 '24 Option Exercise 0.00 155 0 3,548 Jun 03 06:20 PM Tariq Musa Director May 15 '24 Option Exercise 0.00 250 0 3,497 May 16 06:17 PM POTTER MYRTLE S Director May 15 '24 Option Exercise 0.00 69 0 7,651 May 16 06:15 PM EAGLE CRAIG Chief Medical Officer May 15 '24 Option Exercise 0.00 3,717 0 15,169 May 16 06:14 PM Chudova Darya Chief Technology Officer May 15 '24 Option Exercise 0.00 8,705 0 46,106 May 16 06:12 PM Joyce Meghan V. Director May 04 '24 Option Exercise 0.00 66 0 4,654 May 06 05:06 PM Eltoukhy Helmy Co-Chief Executive Officer May 03 '24 Option Exercise 4.18 200,000 836,000 2,292,961 May 06 05:05 PM Talasaz AmirAli Co-Chief Executive Officer May 02 '24 Option Exercise 4.18 283,830 1,186,409 2,193,127 May 06 05:03 PM Krognes Steve E. Director Apr 30 '24 Option Exercise 0.00 154 0 3,393 May 02 05:03 PM Tariq Musa Director Apr 15 '24 Option Exercise 0.00 249 0 3,247 Apr 16 06:36 PM Saia John G. Chief Legal Officer Apr 15 '24 Option Exercise 0.00 7,569 0 28,366 Apr 16 06:35 PM POTTER MYRTLE S Director Apr 15 '24 Option Exercise 0.00 68 0 7,582 Apr 16 06:33 PM Joyce Meghan V. Director Apr 04 '24 Option Exercise 0.00 67 0 4,588 Apr 05 06:29 PM Saia John G. Chief Legal Officer Apr 01 '24 Option Exercise 0.00 974 0 22,305 Apr 02 06:09 PM Kalia Kumud Chief Information Officer Apr 01 '24 Option Exercise 0.00 1,607 0 14,329 Apr 02 06:08 PM Freeman Chris Chief Commercial Officer Apr 01 '24 Option Exercise 0.00 1,929 0 16,502 Apr 02 06:06 PM EAGLE CRAIG Chief Medical Officer Apr 01 '24 Option Exercise 0.00 1,714 0 12,073 Apr 02 06:05 PM Chudova Darya Chief Technology Officer Apr 01 '24 Option Exercise 0.00 1,340 0 36,831 Apr 02 06:04 PM Krognes Steve E. Director Mar 31 '24 Option Exercise 0.00 154 0 3,239 Apr 01 05:25 PM Talasaz AmirAli Co-Chief Executive Officer Mar 31 '24 Option Exercise 0.00 11,461 0 1,913,806 Apr 01 05:23 PM Eltoukhy Helmy Co-Chief Executive Officer Mar 31 '24 Option Exercise 0.00 11,461 0 2,097,470 Apr 01 05:20 PM Kalia Kumud Chief Information Officer Mar 18 '24 Buy 17.82 2,187 38,963 12,722 Mar 19 05:29 PM Tariq Musa Director Mar 15 '24 Option Exercise 0.00 2,998 0 2,998 Mar 18 06:16 PM POTTER MYRTLE S Director Mar 15 '24 Option Exercise 0.00 68 0 7,514 Mar 18 06:14 PM Bell Michael Brian Chief Financial Officer Mar 15 '24 Option Exercise 0.00 1,233 0 12,882 Mar 18 06:12 PM Joyce Meghan V. Director Mar 04 '24 Option Exercise 0.00 66 0 4,621 Mar 05 08:01 PM Joyce Meghan V. Director Mar 04 '24 Sale 19.05 100 1,905 4,521 Mar 05 08:01 PM Saia John G. Chief Legal Officer Mar 01 '24 Option Exercise 0.00 263 0 21,439 Mar 04 06:39 PM Merrill Amelia SVP, People Mar 01 '24 Option Exercise 0.00 158 0 27,540 Mar 04 06:37 PM Kalia Kumud Chief Information Officer Mar 01 '24 Option Exercise 0.00 710 0 10,789 Mar 04 06:35 PM Chudova Darya Chief Technology Officer Mar 01 '24 Option Exercise 0.00 316 0 35,621 Mar 04 06:34 PM Krognes Steve E. Director Feb 29 '24 Option Exercise 0.00 154 0 3,085 Mar 01 05:08 PM POTTER MYRTLE S Director Feb 15 '24 Option Exercise 0.00 69 0 7,446 Feb 16 07:10 PM Joyce Meghan V. Director Feb 04 '24 Option Exercise 0.00 66 0 4,555 Feb 05 08:12 PM Krognes Steve E. Director Jan 31 '24 Option Exercise 0.00 155 0 2,931 Feb 01 05:38 PM Chudova Darya Chief Technology Officer Jan 16 '24 Option Exercise 8.80 6,626 58,309 35,305 Jan 16 07:44 PM POTTER MYRTLE S Director Jan 15 '24 Option Exercise 0.00 68 0 7,377 Jan 16 07:43 PM Bell Michael Brian Chief Financial Officer Jan 15 '24 Option Exercise 0.00 3,308 0 13,005 Jan 16 07:41 PM Kalia Kumud Chief Information Officer Jan 07 '24 Option Exercise 0.00 5,376 0 12,250 Jan 08 07:45 PM Joyce Meghan V. Director Jan 04 '24 Option Exercise 0.00 67 0 4,489 Jan 05 04:58 PM Saia John G. Chief Legal Officer Jan 01 '24 Option Exercise 0.00 974 0 21,576 Jan 03 07:51 PM Merrill Amelia SVP, People Jan 01 '24 Option Exercise 0.00 482 0 27,580 Jan 03 07:49 PM Kalia Kumud Chief Information Officer Jan 01 '24 Option Exercise 0.00 1,607 0 7,533 Jan 03 07:48 PM Freeman Chris Chief Commercial Officer Jan 01 '24 Option Exercise 0.00 1,928 0 15,207 Jan 03 07:45 PM EAGLE CRAIG Chief Medical Officer Jan 01 '24 Option Exercise 0.00 1,714 0 11,062 Jan 03 07:44 PM Chudova Darya Chief Technology Officer Jan 01 '24 Option Exercise 0.00 1,339 0 29,228 Jan 03 07:42 PM Krognes Steve E. Director Dec 31 '23 Option Exercise 0.00 154 0 2,776 Jan 02 06:06 PM POTTER MYRTLE S Director Dec 15 '23 Option Exercise 0.00 69 0 7,309 Dec 18 05:39 PM Bell Michael Brian Chief Financial Officer Dec 15 '23 Option Exercise 0.00 1,233 0 10,124 Dec 18 05:37 PM Joyce Meghan V. Director Dec 04 '23 Option Exercise 0.00 66 0 4,522 Dec 05 05:01 PM Joyce Meghan V. Director Dec 04 '23 Sale 26.34 100 2,634 4,422 Dec 05 05:01 PM Saia John G. Chief Legal Officer Dec 01 '23 Option Exercise 0.00 263 0 20,733 Dec 04 06:28 PM Merrill Amelia SVP, People Dec 01 '23 Option Exercise 0.00 158 0 27,153 Dec 04 06:26 PM Kalia Kumud Chief Information Officer Dec 01 '23 Option Exercise 0.00 710 0 12,079 Dec 04 06:25 PM Kalia Kumud Chief Information Officer Dec 01 '23 Sale 26.37 5,800 152,954 5,926 Dec 04 06:25 PM Chudova Darya Chief Technology Officer Dec 01 '23 Option Exercise 0.00 315 0 27,998 Dec 04 06:24 PM Krognes Steve E. Director Nov 30 '23 Option Exercise 0.00 154 0 2,622 Dec 04 06:22 PM Chudova Darya Chief Technology Officer Nov 15 '23 Option Exercise 8.80 4,000 35,200 27,683 Nov 16 05:04 PM POTTER MYRTLE S Director Nov 15 '23 Option Exercise 0.00 68 0 7,240 Nov 16 05:02 PM Joyce Meghan V. Director Nov 04 '23 Option Exercise 0.00 66 0 4,456 Nov 06 05:40 PM Krognes Steve E. Director Oct 31 '23 Option Exercise 0.00 154 0 2,468 Nov 01 08:07 PM POTTER MYRTLE S Director Oct 15 '23 Option Exercise 0.00 68 0 7,172 Oct 16 06:28 PM Joyce Meghan V. Director Oct 04 '23 Option Exercise 0.00 67 0 4,390 Oct 05 06:02 PM
Index -
P/E -
EPS (ttm) -0.97
Insider Own 51.22%
Shs Outstand 17.05M
Perf Week 5.02%
Market Cap 54.60M
Forward P/E -
EPS next Y -0.83
Insider Trans 0.46%
Shs Float 8.48M
Perf Month 28.16%
Income -17.31M
PEG -
EPS next Q -0.29
Inst Own 36.15%
Short Float 0.19%
Perf Quarter 53.92%
Sales 56.66M
P/S 0.96
EPS this Y 28.48%
Inst Trans -0.85%
Short Ratio 0.31
Perf Half Y 60.20%
Book/sh 1.01
P/B 3.10
EPS next Y 12.87%
ROA -30.51%
Short Interest 0.02M
Perf Year 24.11%
Cash/sh 1.41
P/C 2.23
EPS next 5Y -
ROE -69.97%
52W Range 1.30 - 3.71
Perf YTD 57.79%
Dividend Est. -
P/FCF -
EPS past 5Y 2.69%
ROI -43.68%
52W High -15.36%
Beta 1.27
Dividend TTM -
Quick Ratio 4.01
Sales past 5Y 10.63%
Gross Margin 59.13%
52W Low 141.48%
ATR (14) 0.28
Dividend Ex-Date -
Current Ratio 4.32
EPS Y/Y TTM 52.30%
Oper. Margin -27.90%
RSI (14) 58.37
Volatility 9.13% 11.68%
Employees 179
Debt/Eq 1.36
Sales Y/Y TTM 7.05%
Profit Margin -30.56%
Recom 1.33
Target Price 6.25
Option/Short Yes / Yes
LT Debt/Eq 1.25
EPS Q/Q 42.51%
Payout -
Rel Volume 1.20
Prev Close 3.42
Sales Surprise 14.76%
EPS Surprise 52.94%
Sales Q/Q 6.56%
Earnings Aug 05 BMO
Avg Volume 51.65K
Price 3.14
SMA20 2.89%
SMA50 30.49%
SMA200 61.51%
Trades
Volume 62,014
Change -8.19%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-05-22 Downgrade
KeyBanc Capital Markets
Overweight → Sector Weight
Oct-15-21 Resumed
Cowen
Outperform
$26
Apr-15-21 Initiated
Canaccord Genuity
Buy
$25
Nov-10-20 Initiated
KeyBanc Capital Markets
Overweight
$32
Oct-08-20 Initiated
BTIG Research
Buy
$18
Jun-02-20 Resumed
Cantor Fitzgerald
Overweight
$19 → $20
Oct-14-19 Initiated
William Blair
Outperform
Oct-14-19 Initiated
Cowen
Outperform
$17
Oct-14-19 Initiated
Cantor Fitzgerald
Overweight
$18
Sep-04-24 04:05PM
Aug-29-24 09:55AM
Aug-26-24 08:50AM
Aug-09-24 09:15AM
Aug-08-24 08:50AM
12:53PM
Loading…
Aug-05-24 12:53PM
09:10AM
08:00AM
Aug-02-24 09:00AM
Aug-01-24 09:00AM
Jul-22-24 09:00AM
Jun-13-24 08:50AM
May-15-24 05:01AM
May-13-24 12:53PM
09:10AM
08:00AM
Loading…
08:00AM
May-06-24 04:05PM
Apr-30-24 04:05PM
Apr-26-24 08:30AM
Mar-19-24 09:37AM
01:55AM
(Thomson Reuters StreetEvents)
Mar-18-24 12:52PM
09:25AM
08:00AM
Mar-08-24 09:00AM
Mar-07-24 04:05PM
Feb-06-24 08:50AM
Jan-30-24 04:05PM
Jan-07-24 12:00PM
Nov-13-23 04:05PM
04:05PM
Loading…
Nov-09-23 04:05PM
Nov-02-23 04:05PM
Oct-30-23 04:05PM
(GlobeNewswire) +6.75%
+6.08%
Sep-28-23 04:05PM
Sep-12-23 04:05PM
Aug-09-23 10:47AM
Aug-08-23 04:13AM
(Thomson Reuters StreetEvents)
Aug-07-23 09:15AM
08:00AM
Jul-26-23 04:05PM
Jul-25-23 04:05PM
Jul-24-23 04:05PM
07:33AM
Jun-13-23 08:19AM
May-30-23 09:00AM
May-17-23 07:11AM
May-16-23 11:03AM
(Thomson Reuters StreetEvents) +19.51%
May-15-23 05:55PM
04:05PM
May-01-23 04:05PM
Apr-24-23 04:05PM
Mar-24-23 08:16AM
Mar-22-23 06:12AM
Mar-21-23 07:40AM
(Thomson Reuters StreetEvents)
Mar-20-23 05:25PM
04:05PM
Mar-06-23 04:05PM
Feb-27-23 09:00AM
Feb-14-23 06:19AM
Jan-30-23 04:05PM
Jan-23-23 09:00AM
Nov-14-22 07:55PM
04:05PM
Nov-08-22 04:05PM
Oct-31-22 04:05PM
Oct-17-22 09:00AM
Oct-04-22 08:25AM
Sep-20-22 04:05PM
Sep-19-22 10:20AM
Sep-01-22 04:05PM
Aug-05-22 12:00PM
Aug-04-22 06:55PM
04:06PM
04:05PM
Jul-25-22 04:05PM
(GlobeNewswire) +8.23%
-6.11%
Jul-21-22 04:05PM
Jul-05-22 08:25AM
Jun-21-22 08:10AM
Jun-09-22 08:25AM
May-26-22 04:05PM
May-16-22 04:05PM
May-11-22 05:55PM
04:06PM
04:05PM
May-10-22 10:45AM
May-03-22 05:15PM
May-01-22 12:00PM
Apr-25-22 04:05PM
Apr-20-22 04:05PM
Apr-12-22 07:22AM
Mar-30-22 08:25AM
Mar-22-22 10:00PM
05:25PM
04:06PM
04:05PM
Mar-16-22 04:05PM
Mar-09-22 05:35PM
04:05PM
Mar-08-22 04:05PM
Mar-07-22 08:05AM
Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Adawi Kamal Officer Aug 09 '24 Proposed Sale 2.76 52,624 145,242 Aug 09 05:08 PM ABALLI JOHN President and CEO May 16 '24 Buy 1.92 40,401 77,570 40,401 May 16 08:02 PM Adawi Kamal CFO and Corporate Secretary Mar 04 '24 Sale 1.91 12,784 24,407 243,749 Mar 06 04:05 PM Adawi Kamal CFO and Corporate Secretary Feb 06 '24 Sale 1.95 6,738 13,133 181,533 Feb 08 04:05 PM ABALLI JOHN President and CEO Oct 17 '23 Sale 1.75 33,819 59,018 415,984 Oct 18 04:05 PM
Index S&P 500
P/E 42.52
EPS (ttm) 5.27
Insider Own 0.35%
Shs Outstand 83.90M
Perf Week -2.52%
Market Cap 18.80B
Forward P/E 14.09
EPS next Y 15.89
Insider Trans -15.48%
Shs Float 83.67M
Perf Month 2.07%
Income 449.50M
PEG 4.61
EPS next Q 3.53
Inst Own 96.44%
Short Float 2.00%
Perf Quarter 12.85%
Sales 12.49B
P/S 1.51
EPS this Y 7.97%
Inst Trans -2.81%
Short Ratio 2.95
Perf Half Y 2.54%
Book/sh 95.53
P/B 2.34
EPS next Y 8.55%
ROA 2.61%
Short Interest 1.67M
Perf Year 9.44%
Cash/sh 3.16
P/C 70.91
EPS next 5Y 9.23%
ROE 5.35%
52W Range 191.97 - 238.46
Perf YTD -1.49%
Dividend Est. 2.93 (1.31%)
P/FCF 22.06
EPS past 5Y -11.14%
ROI 3.82%
52W High -6.10%
Beta 1.05
Dividend TTM 2.88 (1.29%)
Quick Ratio 0.77
Sales past 5Y 2.87%
Gross Margin 26.10%
52W Low 16.64%
ATR (14) 4.35
Dividend Ex-Date Aug 29, 2024
Current Ratio 0.88
EPS Y/Y TTM -43.06%
Oper. Margin 9.09%
RSI (14) 47.77
Volatility 1.83% 1.76%
Employees 67000
Debt/Eq 0.75
Sales Y/Y TTM -11.38%
Profit Margin 3.60%
Recom 1.78
Target Price 254.64
Option/Short Yes / Yes
LT Debt/Eq 0.47
EPS Q/Q 14.74%
Payout 60.36%
Rel Volume 0.86
Prev Close 227.34
Sales Surprise 1.11%
EPS Surprise 4.34%
Sales Q/Q 6.17%
Earnings Aug 01 BMO
Avg Volume 566.81K
Price 223.91
SMA20 -1.58%
SMA50 2.80%
SMA200 4.46%
Trades
Volume 488,211
Change -1.51%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-25-24 Upgrade
Argus
Hold → Buy
$250
Feb-26-24 Initiated
Leerink Partners
Outperform
$260
Feb-09-24 Initiated
Evercore ISI
In-line
$240
Jan-03-24 Initiated
Barclays
Equal Weight
$222
Sep-06-23 Initiated
HSBC Securities
Hold
$210
Dec-12-22 Downgrade
Citigroup
Buy → Neutral
$275 → $250
Sep-19-22 Downgrade
Argus
Buy → Hold
Aug-22-22 Resumed
Morgan Stanley
Overweight
$300
Jan-28-22 Downgrade
Deutsche Bank
Buy → Hold
$330 → $294
Jan-11-21 Upgrade
Argus
Hold → Buy
$245
Jan-11-21 Downgrade
Wolfe Research
Peer Perform → Underperform
Jan-08-21 Downgrade
Wolfe Research
Outperform → Peer Perform
Jul-14-20 Upgrade
BofA Securities
Neutral → Buy
$194 → $220
Jul-13-20 Upgrade
Wolfe Research
Peer Perform → Outperform
Jun-02-20 Resumed
Deutsche Bank
Buy
$210
May-15-20 Upgrade
Mizuho
Neutral → Buy
$158 → $186
Apr-29-20 Downgrade
KeyBanc Capital Markets
Overweight → Sector Weight
Apr-27-20 Upgrade
Wolfe Research
Underperform → Peer Perform
Apr-27-20 Upgrade
Citigroup
Neutral → Buy
$204 → $214
Jan-08-20 Initiated
Wells Fargo
Overweight
$210
Show Previous Ratings
Sep-03-24 04:09PM
Aug-27-24 07:05AM
Aug-22-24 08:52AM
Aug-21-24 01:01PM
Aug-19-24 01:01PM
12:42PM
Loading…
Aug-14-24 12:42PM
Aug-07-24 11:00AM
Aug-06-24 12:47AM
Aug-05-24 07:00AM
04:12AM
Aug-03-24 01:05AM
Aug-02-24 01:12PM
(Investor's Business Daily)
08:30AM
06:31AM
(Thomson Reuters StreetEvents)
Aug-01-24 07:21PM
(Morningstar Research) +8.33%
03:02PM
Loading…
03:02PM
01:31PM
11:49AM
09:47AM
09:30AM
08:10AM
07:28AM
07:08AM
(Associated Press Finance)
06:57AM
Jul-31-24 06:00AM
Jul-30-24 07:00AM
Jul-25-24 10:02AM
06:59AM
Jul-22-24 09:27AM
Jul-12-24 08:36AM
10:00AM
Loading…
Jul-09-24 10:00AM
Jul-02-24 07:36AM
Jul-01-24 07:00AM
Jun-20-24 02:20PM
Jun-18-24 06:53AM
06:13AM
(Pharmaceutical Technology)
Jun-17-24 08:00AM
Jun-04-24 07:54AM
07:32AM
Jun-03-24 07:00AM
May-30-24 07:00AM
May-28-24 06:59AM
May-21-24 09:40AM
May-16-24 11:00AM
09:49AM
06:22AM
05:42AM
May-15-24 08:00AM
May-09-24 10:41AM
May-08-24 06:59AM
06:56AM
(Thomson Reuters StreetEvents)
03:44AM
May-07-24 04:05PM
May-02-24 02:22AM
May-01-24 01:03AM
Apr-30-24 01:58PM
08:41AM
Apr-29-24 10:17AM
07:00AM
Apr-26-24 11:14AM
10:34AM
07:55AM
01:06AM
(Thomson Reuters StreetEvents)
Apr-25-24 01:41PM
01:11PM
12:45PM
10:18AM
09:30AM
09:22AM
08:35AM
07:09AM
07:06AM
(Associated Press Finance)
06:58AM
Apr-24-24 10:25PM
10:23PM
09:27PM
09:19PM
Apr-22-24 09:16AM
Apr-19-24 05:34AM
Apr-18-24 12:10PM
10:01AM
Apr-16-24 08:42AM
Apr-15-24 07:00AM
Apr-12-24 09:10AM
Apr-11-24 06:59AM
Apr-10-24 06:49AM
Apr-09-24 09:03AM
Apr-08-24 09:34AM
07:09AM
07:03AM
07:00AM
Apr-05-24 07:00AM
Apr-03-24 11:01AM
11:00AM
Apr-02-24 11:20AM
07:00AM
Apr-01-24 12:42PM
08:00AM
Mar-30-24 01:30AM
Mar-29-24 09:00AM
Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
DiVincenzo Jonathan P. Officer Sep 03 '24 Proposed Sale 229.66 5,460 1,253,956 Sep 03 02:23 PM van der Vaart Sandra D EVP, Chief Legal Officer Aug 19 '24 Sale 227.05 2,000 454,100 3,670 Aug 21 09:08 AM van der Vaart Sandra D Officer Aug 19 '24 Proposed Sale 227.05 2,000 454,100 Aug 19 11:44 AM EISENBERG GLENN A Chief Financial Officer, EVP Aug 15 '24 Sale 223.99 15,000 3,359,825 31,289 Aug 19 10:22 AM EISENBERG GLENN A Officer Aug 15 '24 Proposed Sale 223.99 15,000 3,359,825 Aug 15 06:02 PM ANDERSON KERRII B Director Aug 08 '24 Sale 225.00 586 131,850 14,722 Aug 09 10:16 AM ANDERSON KERRII B Director Aug 07 '24 Sale 225.00 414 93,150 15,308 Aug 09 10:16 AM KERRII B ANDERSON Director Aug 07 '24 Proposed Sale 225.87 1,000 225,870 Aug 07 04:12 PM BERBERIAN LANCE EVP, CIO & CTO Aug 05 '24 Sale 229.10 12,093 2,770,552 15,921 Aug 07 08:47 AM BERBERIAN LANCE Officer Aug 05 '24 Proposed Sale 229.10 12,093 2,770,554 Aug 05 05:13 PM van der Vaart Sandra D EVP, Chief Legal Officer May 14 '24 Sale 210.83 2,000 421,655 5,637 May 16 08:02 AM ANDERSON KERRII B Director Apr 30 '24 Sale 204.13 250 51,034 15,972 May 02 04:29 PM ANDERSON KERRII B Director May 02 '24 Sale 200.10 250 50,025 15,722 May 02 04:29 PM Wilkinson Peter J SVP, Chief Accounting Officer Apr 29 '24 Sale 204.33 2,439 498,358 2,087 May 01 06:29 PM Schroeder Mark S EVP, Pres Diagnostics & COO Apr 01 '24 Sale 217.29 6,477 1,407,387 5,036 Apr 03 08:35 AM Summy Amy B. EVP, Chief Marketing Officer Apr 01 '24 Sale 217.29 3,500 760,515 3,975 Apr 03 08:34 AM van der Vaart Sandra D EVP, Chief Legal Officer Mar 28 '24 Sale 216.74 3,553 770,077 7,637 Mar 29 05:54 PM Schroeder Mark S EVP, Pres Diagnostics & COO Mar 07 '24 Option Exercise 117.09 2,119 248,114 10,084 Mar 11 08:59 AM Schroeder Mark S EVP, Pres Diagnostics & COO Mar 07 '24 Sale 218.45 5,048 1,102,736 5,036 Mar 11 08:59 AM Summy Amy B. EVP, Chief Marketing Officer Mar 07 '24 Sale 218.45 227 49,588 3,859 Mar 11 08:56 AM EISENBERG GLENN A Chief Financial Officer, EVP Feb 21 '24 Option Exercise 163.63 14,054 2,299,656 58,099 Feb 22 03:05 PM EISENBERG GLENN A Chief Financial Officer, EVP Feb 21 '24 Sale 215.97 34,504 7,451,866 23,595 Feb 22 03:05 PM DiVincenzo Jonathan P. EVP, Pres, Central Labs & Intl Feb 21 '24 Sale 215.49 500 107,745 3,401 Feb 22 03:04 PM van der Vaart Sandra D EVP, Chief Legal Officer Feb 13 '24 Sale 226.45 237 53,669 7,637 Feb 15 08:32 AM van der Vaart Sandra D EVP, Chief Legal Officer Feb 08 '24 Sale 222.06 259 57,514 7,637 Feb 09 12:19 PM van der Vaart Sandra D EVP, Chief Legal Officer Feb 05 '24 Sale 220.57 193 42,570 7,637 Feb 06 03:47 PM Wilkinson Peter J SVP, Chief Accounting Officer Nov 16 '23 Sale 210.71 1,384 291,627 2,087 Nov 20 12:23 PM
Index -
P/E -
EPS (ttm) -0.46
Insider Own 59.89%
Shs Outstand 96.24M
Perf Week 0.00%
Market Cap 268.58M
Forward P/E -
EPS next Y -0.22
Insider Trans -0.01%
Shs Float 58.23M
Perf Month 16.35%
Income -44.51M
PEG -
EPS next Q -0.07
Inst Own 36.81%
Short Float 0.73%
Perf Quarter 42.31%
Sales 60.90M
P/S 4.41
EPS this Y 45.63%
Inst Trans 12.06%
Short Ratio 2.90
Perf Half Y 23.33%
Book/sh 0.25
P/B 7.41
EPS next Y 37.93%
ROA -46.01%
Short Interest 0.42M
Perf Year 30.74%
Cash/sh 0.29
P/C 6.35
EPS next 5Y -
ROE -304.17%
52W Range 1.15 - 2.21
Perf YTD 0.54%
Dividend Est. -
P/FCF -
EPS past 5Y 8.42%
ROI -45.63%
52W High -16.29%
Beta 1.22
Dividend TTM -
Quick Ratio 3.21
Sales past 5Y 24.79%
Gross Margin 77.58%
52W Low 60.87%
ATR (14) 0.10
Dividend Ex-Date -
Current Ratio 3.28
EPS Y/Y TTM 58.10%
Oper. Margin -54.42%
RSI (14) 57.56
Volatility 7.38% 6.23%
Employees 217
Debt/Eq 1.70
Sales Y/Y TTM 46.25%
Profit Margin -73.08%
Recom 1.00
Target Price 3.12
Option/Short Yes / Yes
LT Debt/Eq 1.69
EPS Q/Q 50.03%
Payout -
Rel Volume 0.63
Prev Close 1.85
Sales Surprise 10.94%
EPS Surprise 13.14%
Sales Q/Q 50.99%
Earnings Aug 07 AMC
Avg Volume 146.05K
Price 1.85
SMA20 4.01%
SMA50 9.16%
SMA200 15.53%
Trades
Volume 92,363
Change 0.00%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-26-24 Initiated
Craig Hallum
Buy
$3
May-13-24 Initiated
TD Cowen
Buy
$2.80
May-03-24 Initiated
Lake Street
Buy
$3
Nov-17-21 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$21 → $11
Nov-23-20 Initiated
William Blair
Outperform
Nov-23-20 Initiated
Morgan Stanley
Overweight
$20
Nov-23-20 Initiated
Canaccord Genuity
Buy
$26
Nov-23-20 Initiated
BTIG Research
Buy
$22
Sep-05-24 06:00AM
Aug-08-24 10:23AM
(Thomson Reuters StreetEvents)
Aug-07-24 06:05PM
04:01PM
Aug-06-24 06:00AM
06:00AM
Loading…
Jul-24-24 06:00AM
Jun-18-24 08:13AM
May-28-24 06:00AM
May-21-24 06:00AM
May-10-24 05:59PM
03:55PM
May-09-24 03:46AM
May-08-24 09:00PM
05:20PM
04:01PM
06:00AM
Loading…
May-07-24 06:00AM
Apr-24-24 06:00AM
Apr-09-24 05:00PM
Apr-05-24 07:17AM
Mar-25-24 06:00AM
Mar-04-24 09:04AM
Mar-01-24 10:40PM
(Thomson Reuters StreetEvents)
06:31AM
06:00AM
Feb-26-24 06:00AM
Feb-16-24 06:00AM
Feb-13-24 03:00AM
Jan-26-24 09:04AM
Nov-14-23 06:00AM
Nov-09-23 06:00AM
04:01PM
Loading…
Nov-07-23 04:01PM
Oct-24-23 06:00AM
Oct-03-23 06:00AM
Sep-07-23 06:00AM
Sep-05-23 06:00AM
Aug-22-23 06:00AM
Aug-09-23 10:25AM
Aug-08-23 08:38AM
(Thomson Reuters StreetEvents)
Aug-07-23 05:15PM
04:01PM
Aug-01-23 06:00AM
Jul-26-23 07:58AM
Jul-24-23 06:00AM
Jul-12-23 06:00AM
Jul-06-23 09:11AM
Jun-27-23 06:00AM
Jun-01-23 06:00AM
May-31-23 06:00AM
May-28-23 08:09AM
May-25-23 06:00AM
May-24-23 06:00AM
May-18-23 07:00AM
May-12-23 11:10AM
(Thomson Reuters StreetEvents) -12.28%
May-11-23 05:25PM
04:01PM
May-09-23 06:15PM
Apr-27-23 06:00AM
Apr-12-23 06:53AM
Mar-15-23 09:31AM
(Simply Wall St.) +15.24%
Mar-08-23 07:14AM
Mar-06-23 07:25AM
06:00AM
Feb-28-23 06:00AM
Feb-21-23 06:00AM
Feb-16-23 06:27AM
Dec-19-22 06:00AM
Dec-16-22 04:01PM
Dec-12-22 06:00AM
Nov-21-22 04:01PM
(Business Wire) -7.14%
+13.85%
Nov-17-22 12:26AM
Nov-16-22 04:05PM
04:01PM
Nov-10-22 09:00AM
Nov-09-22 05:33AM
Nov-03-22 07:15AM
06:00AM
Oct-20-22 06:00AM
Oct-17-22 05:05PM
(American City Business Journals)
06:00AM
Oct-12-22 06:00AM
Oct-11-22 06:00AM
Sep-06-22 06:00AM
Aug-09-22 06:00AM
Aug-06-22 04:30AM
Aug-04-22 07:15AM
06:00AM
Aug-03-22 06:00AM
Jul-30-22 10:44AM
Jul-20-22 06:00AM
Jul-19-22 06:00AM
Jun-22-22 09:19AM
Jun-15-22 10:11AM
Jun-07-22 06:00AM
Jun-03-22 06:00AM
Jun-01-22 06:00AM
May-17-22 06:00AM
May-12-22 06:00AM
May-11-22 07:15AM
06:00AM
Apr-27-22 06:00AM
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Vazquez Chris Chief Accounting Officer Aug 09 '24 Sale 1.60 155 248 11,242 Aug 12 07:24 PM Vazquez Chris Chief Accounting Officer Aug 12 '24 Sale 1.57 54 85 11,188 Aug 12 07:24 PM Pestano Gary Anthony Chief Development Officer Aug 09 '24 Sale 1.60 320 512 126,187 Aug 12 07:24 PM Pestano Gary Anthony Chief Development Officer Aug 12 '24 Sale 1.57 111 174 126,076 Aug 12 07:24 PM O'Kane Kieran Chief Commercial Officer Aug 09 '24 Sale 1.60 345 552 89,748 Aug 12 07:24 PM O'Kane Kieran Chief Commercial Officer Aug 12 '24 Sale 1.57 120 189 89,628 Aug 12 07:24 PM Hutton Scott President & CEO Aug 09 '24 Sale 1.60 2,781 4,452 519,331 Aug 12 07:23 PM Hutton Scott President & CEO Aug 12 '24 Sale 1.57 963 1,514 518,368 Aug 12 07:23 PM Cowie Robin Harper CFO, Sec'y & Treasurer Aug 09 '24 Sale 1.60 724 1,159 191,402 Aug 12 07:23 PM Cowie Robin Harper CFO, Sec'y & Treasurer Aug 12 '24 Sale 1.57 251 395 191,151 Aug 12 07:23 PM Cowie Robin Harper CFO, Sec'y & Treasurer May 21 '24 Option Exercise 0.42 4,209 1,768 175,889 May 23 07:13 PM Vazquez Chris Chief Accounting Officer May 09 '24 Sale 1.48 244 361 9,915 May 10 05:06 PM Pestano Gary Anthony Chief Development Officer May 09 '24 Sale 1.48 434 642 124,248 May 10 05:06 PM O'Kane Kieran Chief Commercial Officer May 09 '24 Sale 1.48 468 692 75,524 May 10 05:05 PM Hutton Scott President & CEO May 09 '24 Sale 1.48 3,764 5,569 483,780 May 10 05:04 PM Cowie Robin Harper CFO, Sec'y & Treasurer May 09 '24 Sale 1.48 980 1,450 171,680 May 10 05:04 PM Vazquez Chris Chief Accounting Officer Feb 09 '24 Sale 1.92 1,077 2,064 10,470 Feb 12 09:46 PM Vazquez Chris Chief Accounting Officer Feb 12 '24 Sale 1.66 922 1,535 9,548 Feb 12 09:46 PM Pestano Gary Anthony Chief Development Officer Feb 09 '24 Sale 1.92 5,862 11,235 128,272 Feb 12 09:45 PM Pestano Gary Anthony Chief Development Officer Feb 12 '24 Sale 1.66 5,022 8,360 123,250 Feb 12 09:45 PM O'Kane Kieran Chief Commercial Officer Feb 09 '24 Sale 1.92 6,319 12,111 73,417 Feb 12 09:45 PM O'Kane Kieran Chief Commercial Officer Feb 12 '24 Sale 1.66 5,412 9,009 68,005 Feb 12 09:45 PM Hutton Scott President & CEO Feb 09 '24 Sale 1.92 34,682 66,472 494,719 Feb 12 09:45 PM Hutton Scott President & CEO Feb 12 '24 Sale 1.66 29,708 49,455 465,011 Feb 12 09:45 PM Cowie Robin Harper CFO, Sec'y & Treasurer Feb 09 '24 Sale 1.92 10,156 19,465 178,109 Feb 12 09:44 PM Cowie Robin Harper CFO, Sec'y & Treasurer Feb 12 '24 Sale 1.66 8,699 14,481 169,410 Feb 12 09:44 PM Vazquez Chris Chief Accounting Officer Nov 09 '23 Sale 1.27 107 136 6,359 Nov 13 04:51 PM Vazquez Chris Chief Accounting Officer Nov 10 '23 Sale 1.23 108 132 6,251 Nov 13 04:51 PM Pestano Gary Anthony Chief Development Officer Nov 09 '23 Sale 1.27 217 276 104,719 Nov 13 04:51 PM Pestano Gary Anthony Chief Development Officer Nov 10 '23 Sale 1.23 218 267 104,501 Nov 13 04:51 PM O'Kane Kieran Chief Commercial Officer Nov 09 '23 Sale 1.27 234 297 47,947 Nov 13 04:50 PM O'Kane Kieran Chief Commercial Officer Nov 10 '23 Sale 1.23 235 288 47,712 Nov 13 04:50 PM Hutton Scott President & CEO Nov 09 '23 Sale 1.27 1,882 2,391 331,311 Nov 13 04:50 PM Hutton Scott President & CEO Nov 10 '23 Sale 1.23 1,883 2,308 329,428 Nov 13 04:50 PM Cowie Robin Harper CFO, Sec'y & Treasurer Nov 09 '23 Sale 1.27 491 624 137,064 Nov 13 04:50 PM Cowie Robin Harper CFO, Sec'y & Treasurer Nov 10 '23 Sale 1.23 491 602 136,573 Nov 13 04:50 PM
Index -
P/E -
EPS (ttm) -0.96
Insider Own 1.51%
Shs Outstand 184.77M
Perf Week -5.06%
Market Cap 10.92B
Forward P/E 418.12
EPS next Y 0.14
Insider Trans -0.24%
Shs Float 181.97M
Perf Month 5.57%
Income -175.01M
PEG -
EPS next Q -0.19
Inst Own 97.21%
Short Float 7.59%
Perf Quarter 32.33%
Sales 2.61B
P/S 4.18
EPS this Y 17.44%
Inst Trans -1.71%
Short Ratio 5.14
Perf Half Y -3.82%
Book/sh 17.29
P/B 3.42
EPS next Y 115.15%
ROA -2.69%
Short Interest 13.82M
Perf Year -28.06%
Cash/sh 5.12
P/C 11.54
EPS next 5Y -
ROE -5.60%
52W Range 40.62 - 82.96
Perf YTD -20.10%
Dividend Est. -
P/FCF -
EPS past 5Y 4.59%
ROI -3.07%
52W High -28.75%
Beta 1.26
Dividend TTM -
Quick Ratio 1.98
Sales past 5Y 43.88%
Gross Margin 69.63%
52W Low 45.51%
ATR (14) 2.74
Dividend Ex-Date -
Current Ratio 2.17
EPS Y/Y TTM 60.38%
Oper. Margin -10.76%
RSI (14) 54.63
Volatility 5.70% 4.12%
Employees 6600
Debt/Eq 0.87
Sales Y/Y TTM 13.54%
Profit Margin -6.70%
Recom 1.29
Target Price 76.14
Option/Short Yes / Yes
LT Debt/Eq 0.78
EPS Q/Q 80.92%
Payout -
Rel Volume 0.62
Prev Close 60.91
Sales Surprise 1.34%
EPS Surprise 73.55%
Sales Q/Q 12.41%
Earnings Jul 31 AMC
Avg Volume 2.69M
Price 59.11
SMA20 -0.09%
SMA50 13.08%
SMA200 0.45%
Trades
Volume 1,661,506
Change -2.96%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-28-24 Initiated
Wells Fargo
Overweight
$75
Jun-27-24 Initiated
Scotiabank
Sector Outperform
$70
Jun-03-24 Resumed
Jefferies
Buy
$75
Jan-02-24 Upgrade
The Benchmark Company
Hold → Buy
$91
Dec-14-23 Initiated
Guggenheim
Buy
$90
Dec-13-23 Initiated
Wolfe Research
Outperform
$95
Oct-10-23 Upgrade
Piper Sandler
Neutral → Overweight
$90
Sep-28-23 Initiated
Bernstein
Outperform
$83
Aug-02-23 Downgrade
The Benchmark Company
Buy → Hold
May-10-23 Upgrade
Craig Hallum
Hold → Buy
$55 → $85
May-05-23 Initiated
UBS
Neutral
$73
Mar-09-23 Upgrade
Citigroup
Neutral → Buy
$70 → $90
Feb-10-23 Downgrade
Credit Suisse
Outperform → Neutral
$50 → $70
Jan-18-23 Downgrade
Raymond James
Outperform → Mkt Perform
Oct-19-22 Downgrade
Craig Hallum
Buy → Hold
$60 → $35
Aug-25-22 Initiated
Credit Suisse
Outperform
$55
Jun-03-22 Initiated
Piper Sandler
Neutral
$50
Nov-03-21 Downgrade
Raymond James
Strong Buy → Outperform
$160 → $130
Jul-29-21 Reiterated
Stifel
Buy
$165 → $145
Jul-29-21 Reiterated
Oppenheimer
Outperform
$161 → $155
Show Previous Ratings
Aug-30-24 11:31AM
Aug-28-24 06:00AM
Aug-23-24 08:26AM
06:00AM
Aug-22-24 09:55AM
09:23AM
Loading…
09:23AM
08:41AM
Aug-21-24 11:08PM
08:08AM
07:13AM
Aug-20-24 07:00AM
Aug-16-24 07:13AM
Aug-15-24 07:00AM
Aug-14-24 09:19AM
Aug-11-24 02:47PM
09:22PM
Loading…
Aug-10-24 09:22PM
Aug-06-24 09:55AM
Aug-02-24 01:08AM
Aug-01-24 04:02PM
(Investor's Business Daily) +26.77%
10:49AM
09:03AM
12:00AM
Jul-31-24 07:30PM
06:28PM
(Associated Press Finance)
04:05PM
04:05PM
Jul-24-24 10:01AM
Jul-22-24 09:32AM
Jul-16-24 06:06AM
05:57AM
05:53AM
Loading…
05:53AM
Jul-11-24 06:33AM
Jul-08-24 08:30AM
06:00AM
Jul-07-24 05:30AM
(The Wall Street Journal)
Jul-03-24 07:00AM
Jun-20-24 10:13AM
Jun-17-24 12:54PM
Jun-13-24 10:12AM
06:45AM
Jun-07-24 11:30AM
Jun-04-24 07:06AM
Jun-03-24 04:26PM
04:17PM
May-30-24 06:35AM
May-29-24 11:27AM
May-28-24 10:34AM
06:00AM
May-27-24 06:43PM
06:13PM
11:34AM
May-24-24 10:28AM
(The Wall Street Journal) -7.84%
07:11AM
06:05AM
May-22-24 07:30AM
May-21-24 08:56AM
06:05AM
May-17-24 06:27AM
May-10-24 12:27PM
09:22AM
May-09-24 04:02PM
(Investor's Business Daily) -8.96%
12:29PM
11:41AM
11:02AM
09:59AM
(Thomson Reuters StreetEvents)
07:29AM
03:53AM
01:06AM
May-08-24 11:30PM
06:05PM
05:02PM
(Associated Press Finance)
04:05PM
May-07-24 08:00AM
May-06-24 08:52AM
May-01-24 06:00AM
Apr-25-24 08:05PM
(Morningstar Research) -7.04%
Apr-24-24 06:15PM
07:16AM
Apr-22-24 12:44PM
11:10AM
Apr-17-24 06:15PM
Apr-15-24 06:52AM
06:00AM
Apr-12-24 07:00AM
06:49AM
06:40AM
Apr-11-24 06:00AM
Apr-10-24 06:15PM
08:16AM
12:00AM
Apr-09-24 07:37AM
Apr-08-24 12:05PM
07:00AM
(The Wall Street Journal)
06:00AM
Apr-05-24 10:16AM
Apr-04-24 10:15AM
06:05AM
Apr-03-24 09:57AM
Apr-02-24 04:02PM
(Investor's Business Daily)
Mar-29-24 08:09AM
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Baranick Brian EVP, GM, Precision Oncology Aug 05 '24 Option Exercise 0.00 2,712 0 15,991 Aug 06 05:30 PM COWARD D SCOTT Director May 01 '24 Sale 60.15 67 4,030 44,644 May 02 07:00 PM Cunningham Everett Chief Commercial Officer May 01 '24 Sale 60.15 136 8,180 47,042 May 02 07:00 PM Herriott James SVP, General Counsel & Sec May 01 '24 Sale 60.15 30 1,804 9,866 May 02 07:00 PM Elliott Jeffrey Thomas Chief Financial Officer May 01 '24 Sale 60.15 136 8,180 11,795 May 02 07:00 PM Baranick Brian EVP, GM., Precision Oncology May 01 '24 Sale 60.15 110 6,616 13,279 May 02 07:00 PM Condella Sarah EVP, Human Resources May 01 '24 Sale 60.15 102 6,135 72,611 May 02 07:00 PM ORVILLE JACOB A General Manager, Screening May 01 '24 Sale 60.15 102 6,135 14,440 May 02 07:00 PM Conroy Kevin T President and CEO May 01 '24 Sale 60.15 1,155 69,473 1,156,191 May 02 07:00 PM Condella Sarah EVP, Human Resources Apr 01 '24 Sale 70.00 2,000 140,000 71,787 Apr 03 07:30 PM Baranick Brian EVP, GM., Precision Oncology Apr 02 '24 Sale 79.43 924 73,393 13,171 Apr 03 07:30 PM Condella Sarah EVP, Human Resources Mar 28 '24 Sale 70.00 2,000 140,000 73,787 Apr 01 04:30 PM ORVILLE JACOB A General Manager, Screening Feb 29 '24 Option Exercise 0.00 4,724 0 16,478 Mar 04 08:42 PM ORVILLE JACOB A General Manager, Screening Mar 01 '24 Sale 59.32 2,154 127,775 14,324 Mar 04 08:42 PM LEVANGIE DANIEL J Director Mar 01 '24 Sale 57.50 5,000 287,500 22,975 Mar 04 08:42 PM Herriott James General Counsel Feb 29 '24 Option Exercise 0.00 1,890 0 9,987 Mar 04 08:41 PM Herriott James General Counsel Mar 01 '24 Sale 59.32 862 51,134 9,125 Mar 04 08:41 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 29 '24 Option Exercise 0.00 5,291 0 13,345 Mar 04 08:40 PM Elliott Jeffrey Thomas Chief Financial Officer Mar 01 '24 Sale 59.32 2,412 143,080 10,933 Mar 04 08:40 PM Doyle James Edward Director Mar 01 '24 Sale 57.50 2,000 115,000 50,110 Mar 04 08:39 PM Cunningham Everett Chief Commercial Officer Feb 29 '24 Option Exercise 0.00 5,291 0 48,591 Mar 04 08:38 PM Cunningham Everett Chief Commercial Officer Mar 01 '24 Sale 59.32 2,412 143,080 46,179 Mar 04 08:38 PM Conroy Kevin T President and CEO Feb 29 '24 Option Exercise 0.00 18,143 0 1,307,767 Mar 04 08:38 PM Conroy Kevin T President and CEO Mar 01 '24 Sale 59.32 8,271 490,636 1,299,496 Mar 04 08:38 PM Condella Sarah EVP, Human Resources Feb 29 '24 Option Exercise 0.00 3,779 0 77,511 Mar 04 08:37 PM Condella Sarah EVP, Human Resources Mar 01 '24 Sale 59.32 1,724 102,268 75,787 Mar 04 08:37 PM Baranick Brian Gen. Mgr., Precision Oncology Feb 29 '24 Option Exercise 0.00 4,724 0 16,418 Mar 04 08:36 PM Baranick Brian Gen. Mgr., Precision Oncology Mar 01 '24 Sale 59.32 2,323 137,800 14,095 Mar 04 08:36 PM ORVILLE JACOB A General Manager, Screening Feb 26 '24 Option Exercise 0.00 3,954 0 13,633 Feb 28 07:38 PM ORVILLE JACOB A General Manager, Screening Feb 27 '24 Sale 56.89 1,879 106,896 11,754 Feb 28 07:38 PM Herriott James General Counsel Feb 26 '24 Option Exercise 0.00 1,648 0 8,881 Feb 28 07:38 PM Herriott James General Counsel Feb 27 '24 Sale 56.89 784 44,602 8,097 Feb 28 07:38 PM Cunningham Everett Chief Commercial Officer Feb 26 '24 Option Exercise 0.00 7,678 0 46,948 Feb 28 07:37 PM Cunningham Everett Chief Commercial Officer Feb 27 '24 Sale 56.89 3,648 207,535 43,300 Feb 28 07:37 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 26 '24 Option Exercise 0.00 5,701 0 10,764 Feb 28 07:36 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 27 '24 Sale 56.89 2,710 154,172 8,054 Feb 28 07:36 PM Conroy Kevin T President and CEO Feb 26 '24 Option Exercise 0.00 13,181 0 1,295,887 Feb 28 07:35 PM Conroy Kevin T President and CEO Feb 27 '24 Sale 56.89 6,263 356,302 1,289,624 Feb 28 07:35 PM Condella Sarah EVP, Human Resources Feb 26 '24 Option Exercise 0.00 3,954 0 75,612 Feb 28 07:35 PM Condella Sarah EVP, Human Resources Feb 27 '24 Sale 56.89 1,880 106,953 73,732 Feb 28 07:35 PM Baranick Brian Gen. Mgr., Precision Oncology Feb 26 '24 Option Exercise 0.00 3,954 0 13,721 Feb 28 07:34 PM Baranick Brian Gen. Mgr., Precision Oncology Feb 27 '24 Sale 56.89 2,027 115,316 11,694 Feb 28 07:34 PM Conroy Kevin T President and CEO Feb 23 '24 Option Exercise 13.96 102,837 1,435,605 1,344,266 Feb 26 05:00 PM Condella Sarah EVP, Human Resources Feb 23 '24 Sale 59.72 1,021 60,974 71,658 Feb 26 05:00 PM ORVILLE JACOB A General Manager, Screening Feb 22 '24 Sale 59.78 1,013 60,557 9,679 Feb 23 08:03 PM Herriott James General Counsel Feb 22 '24 Sale 59.78 291 17,396 7,233 Feb 23 08:02 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 22 '24 Sale 59.78 1,351 80,763 5,063 Feb 23 08:01 PM Cunningham Everett Chief Commercial Officer Feb 22 '24 Sale 59.78 1,350 80,703 39,270 Feb 23 08:00 PM COWARD D SCOTT Director Feb 22 '24 Sale 59.78 663 39,634 44,493 Feb 23 07:59 PM Conroy Kevin T President and CEO Feb 22 '24 Sale 59.78 11,565 691,356 1,241,429 Feb 23 07:59 PM Condella Sarah EVP, Human Resources Feb 22 '24 Sale 59.78 1,013 60,557 72,679 Feb 23 07:57 PM Baranick Brian Gen. Mgr., Precision Oncology Feb 22 '24 Sale 59.78 1,093 65,340 9,767 Feb 23 07:57 PM ORVILLE JACOB A General Manager, Screening Feb 20 '24 Option Exercise 0.00 2,248 0 9,736 Feb 22 07:40 PM ORVILLE JACOB A General Manager, Screening Feb 21 '24 Sale 61.50 1,078 66,297 8,658 Feb 22 07:40 PM Herriott James General Counsel Feb 20 '24 Option Exercise 0.00 864 0 7,358 Feb 22 07:39 PM Herriott James General Counsel Feb 21 '24 Sale 61.50 415 25,522 6,943 Feb 22 07:39 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 20 '24 Option Exercise 0.00 3,112 0 5,196 Feb 22 07:38 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 21 '24 Sale 61.50 1,493 91,820 3,703 Feb 22 07:38 PM COWARD D SCOTT Director Feb 20 '24 Option Exercise 0.00 2,248 0 43,828 Feb 22 07:38 PM COWARD D SCOTT Director Feb 21 '24 Sale 61.50 706 43,419 43,122 Feb 22 07:38 PM Conroy Kevin T President and CEO Feb 20 '24 Option Exercise 0.00 10,374 0 1,234,731 Feb 22 07:37 PM Conroy Kevin T President and CEO Feb 21 '24 Sale 61.50 4,975 305,962 1,229,756 Feb 22 07:37 PM Condella Sarah EVP, Human Resources Feb 20 '24 Option Exercise 0.00 2,248 0 72,737 Feb 22 07:36 PM Condella Sarah EVP, Human Resources Feb 21 '24 Sale 61.50 1,079 66,358 71,658 Feb 22 07:36 PM Baranick Brian Gen. Mgr., Precision Oncology Feb 20 '24 Option Exercise 0.00 1,729 0 9,721 Feb 22 07:36 PM Baranick Brian Gen. Mgr., Precision Oncology Feb 21 '24 Sale 61.50 895 55,042 8,826 Feb 22 07:36 PM ORVILLE JACOB A General Manager, Screening Feb 14 '24 Option Exercise 0.00 2,031 0 8,454 Feb 16 06:26 PM ORVILLE JACOB A General Manager, Screening Feb 15 '24 Sale 61.43 966 59,341 7,488 Feb 16 06:26 PM Herriott James General Counsel Feb 14 '24 Option Exercise 0.00 883 0 6,915 Feb 16 06:25 PM Herriott James General Counsel Feb 15 '24 Sale 61.43 421 25,862 6,494 Feb 16 06:25 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 14 '24 Option Exercise 0.00 3,972 0 3,972 Feb 16 06:24 PM Elliott Jeffrey Thomas Chief Financial Officer Feb 15 '24 Sale 61.43 1,888 115,980 2,084 Feb 16 06:24 PM COWARD D SCOTT Director Feb 14 '24 Option Exercise 0.00 3,972 0 42,956 Feb 16 06:23 PM COWARD D SCOTT Director Feb 15 '24 Sale 61.43 1,376 84,528 41,580 Feb 16 06:23 PM Conroy Kevin T President and CEO Feb 14 '24 Option Exercise 0.00 31,133 0 1,239,148 Feb 16 06:22 PM Conroy Kevin T President and CEO Feb 15 '24 Sale 61.43 14,791 908,611 1,224,357 Feb 16 06:22 PM Condella Sarah EVP, Human Resources Feb 14 '24 Option Exercise 0.00 2,031 0 71,454 Feb 16 06:21 PM Condella Sarah EVP, Human Resources Feb 15 '24 Sale 61.43 965 59,280 70,489 Feb 16 06:21 PM Condella Sarah EVP, Human Resources Jan 02 '24 Sale 73.50 2,000 147,000 69,423 Jan 04 05:19 PM Baranick Brian Gen. Mgr., Precision Oncology Jan 02 '24 Sale 73.50 879 64,606 7,992 Jan 04 05:17 PM Condella Sarah EVP, Human Resources Dec 14 '23 Sale 70.00 2,000 140,000 71,423 Dec 18 07:49 PM Cunningham Everett Chief Commercial Officer Oct 11 '23 Option Exercise 0.00 27,504 0 50,916 Oct 13 07:59 PM Cunningham Everett Chief Commercial Officer Oct 12 '23 Sale 66.49 13,007 864,835 37,909 Oct 13 07:59 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite